INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236501, 'Galactose', 'Dexamethasone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Ipratropium, Cromoglicic acid, Nedocromil, Beclomethasone dipropionate, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Vitamin A, Caffeine, Metyrapone, Histamine, Indocyanine green, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236731/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236502, 'Galactose', 'Sodium bicarbonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium chloride, Chlorhexidine, Neomycin, Sodium acetate, Zinc sulfate, Magnesium sulfate, Arginine, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236732/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236503, 'Galactose', 'Cefepime', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, Metyrapone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236733/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236504, 'Galactose', 'Ursodeoxycholic acid', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Maralixibat, Obeticholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, Metyrapone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236734/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236505, 'Clobetasol', 'Bortezomib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Triamcinolone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236735/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236506, 'Clobetasol', 'Adapalene', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Chloramphenicol, Azelaic acid, Fluorometholone, Isotretinoin', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluticasone, Fluocinonide, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236736/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236507, 'Clobetasol', 'Pimecrolimus', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Abrocitinib, Dupilumab, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Beclomethasone dipropionate, Fluocinolone acetonide, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236737/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236508, 'Clobetasol', 'Sucralfate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236738/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236509, 'Clobetasol', 'Zoledronic acid', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tiludronic acid, Vosoritide, Etidronic acid, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Pamidronic acid', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236739/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236510, 'Allopurinol', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236740/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236511, 'Clobetasol', 'Acitretin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Etretinate, Methoxsalen, Trioxsalen', 'Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluticasone, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236741/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236512, 'Clobetasol', 'Montelukast', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236742/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236513, 'Duloxetine', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Maprotiline, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Fluvoxamine, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236743/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236514, 'Clobetasol', 'Valdecoxib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, Meloxicam, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Beclomethasone dipropionate, Fluocinonide, Fluorometholone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236744/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236515, 'Clobetasol', 'Simvastatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236745/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236516, 'Clobetasol', 'Nystatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tamsulosin, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236746/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236517, 'Ibandronate', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tiludronic acid, Vosoritide, Etidronic acid, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Pamidronic acid', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Hydrocortisone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236747/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236518, 'Clobetasol', 'Sulfasalazine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236748/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236519, 'Almotriptan', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More', 'Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluocinonide, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236749/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236520, 'Desloratadine', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, Clemastine, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236750/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236521, 'Ezetimibe', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Rosuvastatin, Perindopril, Niacin, Bempedoic acid, Indapamide, Cholestyramine, Rosuvastatin, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236751/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236522, 'Clobetasol', 'Clarithromycin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Beclomethasone dipropionate, Fluocinonide, Fluorometholone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236752/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236523, 'Clobetasol', 'Tiotropium', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Olodaterol, Ipratropium, Orciprenaline, Pirbuterol, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236753/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236524, 'Fluticasone', 'Clobetasol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Beclomethasone dipropionate, Betamethasone, Fluorometholone', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236754/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236525, 'Fluticasone', 'Bortezomib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236755/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236526, 'Fluticasone', 'Dofetilide', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Propafenone, Tocainide, Procainamide, Mexiletine, Disopyramide, Bretylium, Moricizine, Ibutilide', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236756/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236527, 'Fluticasone', 'Eletriptan', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236757/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236528, 'Fluticasone', 'Pregabalin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236758/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236529, 'Fluticasone', 'Travoprost', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Apraclonidine, Guanethidine, Levobunolol', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236759/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236530, 'Gefitinib', 'Fluticasone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236760/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236531, 'Fluticasone', 'Pimecrolimus', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Abrocitinib, Dupilumab, Tralokinumab, Povidone-iodine', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236761/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236532, 'Fluticasone', 'Sucralfate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236762/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236533, 'Fluticasone', 'Palonosetron', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Rolapitant, Nabilone, Dronabinol', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236763/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236534, 'Fluticasone', 'Sorafenib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236764/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236535, 'Fluticasone', 'Zoledronic acid', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236765/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236536, 'Fluticasone', 'Allopurinol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Ipratropium, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236766/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236537, 'Fluticasone', 'Verteporfin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Aflibercept, Bevacizumab', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236767/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236538, 'Fluticasone', 'Montelukast', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236768/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236539, 'Fluticasone', 'Lenalidomide', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236769/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236540, 'Fluticasone', 'Entacapone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apomorphine, Opicapone, Rasagiline, Tolcapone, Rotigotine, Bromocriptine, Safinamide, Levodopa', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236770/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236541, 'Fluticasone', 'Darifenacin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Ciclesonide, Mometasone furoate, Flunisolide, Cromoglicic acid, Betamethasone, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236771/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236542, 'Fluticasone', 'Cisplatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Mometasone furoate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236772/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236543, 'Fluticasone', 'Erlotinib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Entrectinib, Dabrafenib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236773/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236544, 'Fluticasone', 'Cefdinir', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, Cefmetazole, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236774/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236545, 'Fluticasone', 'Bosentan', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Tioconazole, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236775/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236546, 'Fluticasone', 'Valdecoxib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Flurbiprofen, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236776/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236547, 'Fluticasone', 'Lactulose', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236777/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236548, 'Fluticasone', 'Nystatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Salicylic acid, Thiabendazole, Griseofulvin, Flucytosine, Tioconazole, Chlorphenesin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Sulfadiazine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236778/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236549, 'Fluticasone', 'Sevelamer', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236779/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236550, 'Fluticasone', 'Moexipril', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Trandolapril, Trandolapril', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236780/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236551, 'Fluticasone', 'Methimazole', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Potassium perchlorate, Propylthiouracil', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236781/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236552, 'Fluticasone', 'Sulfasalazine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Tioconazole, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236782/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236553, 'Fluticasone', 'Tadalafil', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236783/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236554, 'Fluticasone', 'Vardenafil', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236784/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236555, 'Fluticasone', 'Bimatoprost', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Apraclonidine, Guanethidine, Levobunolol', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236785/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236556, 'Fluticasone', 'Paricalcitol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236786/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236557, 'Fluticasone', 'Almotriptan', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236787/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236558, 'Fluticasone', 'Misoprostol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Methylergometrine, Dinoprostone, Ergometrine, Oxytocin, Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236788/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236559, 'Fulvestrant', 'Fluticasone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Darolutamide, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236789/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236560, 'Fluticasone', 'Telmisartan', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Eprosartan, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Revefenacin, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236790/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236561, 'Fluticasone', 'Desloratadine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236791/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236562, 'Fluticasone', 'Ezetimibe', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236792/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236563, 'Fluticasone', 'Neomycin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Flurbiprofen, Povidone-iodine, Bacitracin, Kanamycin, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236793/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236564, 'Fluticasone', 'Cinacalcet', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236794/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236565, 'Fluticasone', 'Balsalazide', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Beclomethasone dipropionate, Betamethasone, Olsalazine', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236795/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236566, 'Fluticasone', 'Mercaptopurine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine, Omalizumab, Tezepelumab, Benralizumab, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236796/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236567, 'Fluticasone', 'Tegaserod', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236797/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236568, 'Iloprost', 'Fluticasone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236798/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236569, 'Fluticasone', 'Rosuvastatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Lomitapide, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236799/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236570, 'Fluticasone', 'Atovaquone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Quinacrine, Secnidazole, Furazolidone, Nitazoxanide, Trimetrexate, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236800/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236571, 'Fluticasone', 'Dutasteride', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Silodosin, Solifenacin', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236801/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236572, 'Gemifloxacin', 'Fluticasone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Enoxacin, Levofloxacin, Norfloxacin, Nalidixic acid, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236802/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236573, 'Fluticasone', 'Brinzolamide', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Apraclonidine, Guanethidine, Levobunolol, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236803/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236574, 'Fluticasone', 'Paliperidone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Lurasidone, Mesoridazine, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Budesonide, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236804/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236575, 'Fluticasone', 'Varenicline', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Diamorphine, Acamprosate, Lofexidine, Disulfiram, Levacetylmethadol, Nalmefene, Buprenorphine', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236805/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236576, 'Fluticasone', 'Valganciclovir', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Etravirine, Dolutegravir, More', 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236806/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236577, 'Fluticasone', 'Ambrisentan', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Riociguat, Macitentan, Metyrosine', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236807/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236578, 'Fluticasone', 'Aliskiren', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Eprosartan', 'Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236808/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236579, 'Hydrocortisone butyrate', 'Ramipril', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Hydrochlorothiazide, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236809/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236580, 'Hydrocortisone butyrate', 'Lidocaine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236810/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236581, 'Hydrocortisone butyrate', 'Gefitinib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Methylprednisolone, Betamethasone, Fluorometholone, Triamcinolone, Clobetasol, Beclomethasone dipropionate, Triamcinolone, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236811/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236582, 'Hydrocortisone butyrate', 'Omeprazole', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Clarithromycin, Metronidazole, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236812/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236583, 'Hydrocortisone butyrate', 'Zolpidem', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236813/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236584, 'Hydrocortisone butyrate', 'Allopurinol', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236814/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236585, 'Hydrocortisone butyrate', 'Lansoprazole', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Clarithromycin, Metronidazole, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236815/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236586, 'Hydrocortisone butyrate', 'Oxycodone', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Naltrexone, Oxymorphone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236816/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236587, 'Hydrocortisone butyrate', 'Rofecoxib', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236817/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236588, 'Hydrocortisone butyrate', 'Simvastatin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236818/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236589, 'Hydrocortisone butyrate', 'Ribavirin', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236819/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236590, 'Hydrocortisone butyrate', 'Terbinafine', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236820/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236591, 'Hydrocortisone butyrate', 'Tacrolimus', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236821/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236592, 'Hydrocortisone butyrate', 'Ketotifen', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Olopatadine, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Brimonidine, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Methylprednisolone, Betamethasone, Fluorometholone, Triamcinolone, Clobetasol, Beclomethasone dipropionate, More', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236822/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236593, 'Hydrocortisone butyrate', 'Ursodeoxycholic acid', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Maralixibat, Obeticholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Fluocinonide, Betamethasone, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Betamethasone', 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236823/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236594, 'Pregabalin', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236824/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236595, 'Travoprost', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, Epinephrine, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236825/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236596, 'Allopurinol', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236826/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236597, 'Nystatin', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236827/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236598, 'Tamsulosin', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Terazosin, Alfuzosin, Tadalafil, Finasteride, Silodosin, Dutasteride, Solifenacin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236828/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236599, 'Olopatadine', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Ketotifen, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Flunisolide, Betamethasone, Phenylephrine, Azelastine, Ciclesonide, Mupirocin, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236829/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236600, 'Bimatoprost', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, Epinephrine, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236830/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236601, 'Ezetimibe', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Amlodipine, Ramipril, Atorvastatin, Lovastatin, Perindopril, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Cholestyramine, Fenofibrate, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236831/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236602, 'Rosuvastatin', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Amlodipine, Ramipril, Atorvastatin, Lovastatin, Perindopril, Niacin, Bempedoic acid, Indapamide, Fenofibrate, Cholestyramine, Fenofibrate, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236832/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236603, 'Tiotropium', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Beclomethasone dipropionate, Terbutaline, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Orciprenaline, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236833/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236604, 'Fluticasone', 'Loteprednol etabonate', 'Unknown', 'None', NULL, '-', NULL, '-', NULL, 'Ciclesonide, Umeclidinium, Mometasone furoate, Budesonide, Glycopyrronium, Aclidinium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, More', NULL, 'Unknown', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236834/', '-', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236605, 'Abciximab', 'Alemtuzumab', 'Moderate', 'Coadministration of alemtuzumab with antiplatelet or anticoagulant drugs may increase the risk of bleeding.  Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia.  The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.  Patients should be monitored for increased anticoagulant effects and bleeding complications.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', 'Iloprost, Treprostinil, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236841/', '[1] "Product Information. Campath (alemtuzumab)." Berlex Laboratories  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236606, 'Heparin (flush)', 'Abciximab', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', NULL, 'Caution and monitoring (e.', NULL, 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Acenocoumarol, Selexipag', 'Abciximab, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/236848/', '[1] Passannante A, Macik BG "The heparin flush syndrome: a cause of iatrogenic hemorrhage." Am J Med Sci 296 (1988):  71-3[2] "Product Information. Heparin Sodium in Sodium Chloride (heparin flush)." Baxter Healthcare Corporation  (2022):[3] "Product Information. Canusal (heparin flush)." Wockhardt UK Ltd  (2018):[4] "Product Information. Heparinised Saline (Pfizer) (heparinised saline)." Pfizer Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236607, 'Amphotericin B (lipid complex)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237031/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236608, 'Amphotericin B (lipid complex)', 'Bacitracin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237032/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236609, 'Amphotericin B (lipid complex)', 'Budesonide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.  Potassium supplementation may be necessary.  Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Salbutamol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237034/', '[1] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984):  60-5[2] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42[3] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992):  312[4] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969):  425-32[5] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993):  2110-2[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966):  775-81[7] "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):[8] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995):  656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236610, 'Amphotericin B (lipid complex)', 'Chlorothiazide', 'Moderate', 'The concomitant use of amphotericin and potassium-wasting diuretics may result in increased risk of hypokalemia due to additive effects.', NULL, 'Patients receiving diuretics with amphotericin should be monitored closely for development of hypokalemia.', NULL, 'Patients receiving diuretics with amphotericin should be monitored closely for development of hypokalemia.  Potassium supplementation may be necessary.  Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237035/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236611, 'Amphotericin B (lipid complex)', 'Colistimethate', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237036/', '[1] "Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236612, 'Iloperidone', 'Amphotericin B (lipid complex)', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Probenecid, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237039/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236613, 'Isavuconazonium', 'Amphotericin B (lipid complex)', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin.', NULL, 'Caution is urged if combination therapy is necessary.', NULL, 'Caution is urged if combination therapy is necessary.', 'Antagonism', 'Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237043/', '[1] Saag MS, Powderly WG, Cloud GA, et al. "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992):  83-9[2] "Product Information. Fungizone (amphotericin B)." Apothecon Inc  (2022):[3] "Product Information. Abelcet (amphotericin B lipid complex)." Liposome Company Inc, The[4] "Product Information. Ambisome (amphotericin B liposomal)" Nexstar Pharmaceuticals, San Dimas, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236614, 'Amphotericin B (lipid complex)', 'Mesoridazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237045/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236615, 'Amphotericin B (lipid complex)', 'Micafungin', 'Moderate', 'The concomitant use of micafungin and amphotericin B may increase systemic exposure to amphotericin.  The mechanism is unknown.  Coadministration resulted in a 30% increase in amphotericin exposure.  Micafungin pharmacokinetics were not affected.', NULL, 'The European manufacturers recommend that these drugs should only be coadministered if the potential benefits outweigh the risks.', NULL, 'The European manufacturers recommend that these drugs should only be coadministered if the potential benefits outweigh the risks.  Patients should be monitored for amphotericin toxicity.  The same precaution may be applicable during therapy with other forms of amphotericin B such as liposomal or lipid complex, although clinical data are lacking.', 'Others', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237048/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html"   (2008):[4] Undre NA, Stevenson P, Wilbraham D "Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects." Int J Clin Pharmacol Ther 52 (2014):  237-44', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236616, 'Amphotericin B (lipid complex)', 'Perphenazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Darunavir, Probenecid, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237049/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236617, 'Amphotericin B (lipid complex)', 'Polymyxin B', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Tetracycline, Rifamycin, Ciprofloxacin, Chloramphenicol, Chlorhexidine, Ofloxacin, Tetracycline, Ciprofloxacin, Chlorhexidine, Chloramphenicol, Tinidazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237050/', '[1] "Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236618, 'Amphotericin B (lipid complex)', 'Posaconazole', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin.', NULL, 'Caution is urged if combination therapy is necessary.', NULL, 'Caution is urged if combination therapy is necessary.', 'Antagonism', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Darunavir, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237051/', '[1] Saag MS, Powderly WG, Cloud GA, et al. "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992):  83-9[2] "Product Information. Fungizone (amphotericin B)." Apothecon Inc  (2022):[3] "Product Information. Abelcet (amphotericin B lipid complex)." Liposome Company Inc, The[4] "Product Information. Ambisome (amphotericin B liposomal)" Nexstar Pharmaceuticals, San Dimas, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236619, 'Amphotericin B (lipid complex)', 'Prochlorperazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237052/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236620, 'Amphotericin B (lipid complex)', 'Telavancin', 'Moderate', 'Increased adverse effects are possible when glycopeptide, polypeptide, or polymyxin antibiotics are administered concomitantly with other potentially nephrotoxic and neurotoxic drugs.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', NULL, 'If these drugs must be used together, renal function, auditory and vestibular function, and serum drug concentrations should be monitored.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237054/', '[1] "Product Information. Vancocin (vancomycin)." Lilly, Eli and Company  (2001):[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236621, 'Amphotericin B (lipid complex)', 'Triflupromazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237057/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236622, 'Abemaciclib', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237061/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236623, 'Abemaciclib', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237129/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236624, 'Abemaciclib', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237130/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236625, 'Pralsetinib', 'Acetaminophen', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Salicylic acid, Choline salicylate, Ziconotide, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid, Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, More', 'Entrectinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237143/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236626, 'Berotralstat', 'Aripiprazole', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.  Clinical and laboratory monitoring are recommended following the initiation of berotralstat, and the individual dosage of the concomitant agents adjusted as needed.', 'Metabolism', 'Promazine, Prochlorperazine, Thiothixene, Pimavanserin, Olanzapine, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, Molindone, Paliperidone', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237152/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236627, 'Brigatinib', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Fluphenazine, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Lurasidone, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237155/', '[1] "Product Information. Abilify (ARIPiprazole)." Bristol-Myers Squibb  (2022):[2] "Product Information. Abilify Maintena (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2023):[3] "Product Information. Aristada (ARIPiprazole)." Alkermes, Inc  (2022):[4] "Product Information. Aristada Initio (ARIPiprazole)." Alkermes, Inc  (2022):[5] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[6] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[7] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2023):[8] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2022):[9] "Product Information. Abilify (ARIPiprazole)." Otsuka Australia Pharmaceutical Pty Ltd  (2022):[10] "Product Information. Abilify Maintena (ARIPiprazole)." Lundbeck Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236628, 'Aripiprazole', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237173/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236629, 'Aripiprazole', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', 'Isoflurane, Nitrous oxide, Desflurane, Enflurane, Etomidate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237174/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236630, 'Metreleptin', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, Paliperidone, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Zinc acetate, Nitisinone, Levocarnitine, Laronidase, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237176/', '[1] "Product Information. Abilify (ARIPiprazole)." Bristol-Myers Squibb  (2022):[2] "Product Information. Abilify Maintena (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2023):[3] "Product Information. Aristada (ARIPiprazole)." Alkermes, Inc  (2022):[4] "Product Information. Aristada Initio (ARIPiprazole)." Alkermes, Inc  (2022):[5] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[6] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[7] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2023):[8] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2022):[9] "Product Information. Abilify (ARIPiprazole)." Otsuka Australia Pharmaceutical Pty Ltd  (2022):[10] "Product Information. Abilify Maintena (ARIPiprazole)." Lundbeck Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236631, 'Oritavancin', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Pimozide, Trifluoperazine, More', 'Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237182/', '[1] "Product Information. Abilify (ARIPiprazole)." Bristol-Myers Squibb  (2022):[2] "Product Information. Abilify Maintena (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2023):[3] "Product Information. Aristada (ARIPiprazole)." Alkermes, Inc  (2022):[4] "Product Information. Aristada Initio (ARIPiprazole)." Alkermes, Inc  (2022):[5] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[6] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[7] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2023):[8] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2022):[9] "Product Information. Abilify (ARIPiprazole)." Otsuka Australia Pharmaceutical Pty Ltd  (2022):[10] "Product Information. Abilify Maintena (ARIPiprazole)." Lundbeck Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236632, 'Palbociclib', 'Aripiprazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these isoenzymes.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The manufacturer recommends that aripiprazole dosage be reduced to one-half the normal dosage during concomitant administration with ketoconazole or quinidine, and additional dosage adjustments be made based on clinical evaluation.  No dosage recommendations are available for concomitant administration with less potent CYP450 2D6 or 3A4 inhibitors.', 'Metabolism', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237184/', '[1] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236633, 'Pralsetinib', 'Aripiprazole', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.  ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', 'Amisulpride, Loxapine, Molindone, Thiothixene', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237187/', '[1] Kane JM, Carson WH, Saha AR, et al. "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder." J Clin Psychiatry 63 (2002):  763-71[2] Goodnick PJ, Jerry J, Parra F "Psychotropic drugs and the ECG: focus on the QTc interval." Expert Opin Pharmacother 3 (2002):  479-98[3] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):[4] Keck PE Jr, Marcus R, Tourkodimitris S, et al. "A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania." Am J Psychiatry 160 (2003):  1651-8[5] Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study." J Clin Psychiatry 64 (2003):  1048-56[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Nelson S, Leung JG "Torsades de Pointes After Administration of Low-Dose Aripiprazole (February)." Ann Pharmacother  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236634, 'Relugolix', 'Aripiprazole', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.  ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Norethisterone, Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, Exemestane, Fulvestrant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237189/', '[1] Kane JM, Carson WH, Saha AR, et al. "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder." J Clin Psychiatry 63 (2002):  763-71[2] Goodnick PJ, Jerry J, Parra F "Psychotropic drugs and the ECG: focus on the QTc interval." Expert Opin Pharmacother 3 (2002):  479-98[3] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb  (2002):[4] Keck PE Jr, Marcus R, Tourkodimitris S, et al. "A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania." Am J Psychiatry 160 (2003):  1651-8[5] Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study." J Clin Psychiatry 64 (2003):  1048-56[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Nelson S, Leung JG "Torsades de Pointes After Administration of Low-Dose Aripiprazole (February)." Ann Pharmacother  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236635, 'Safinamide', 'Aripiprazole', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237190/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236636, 'Zanubrutinib', 'Aripiprazole', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole and its active metabolite, dehydro-aripiprazole.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.  The prescribing information for individual aripiprazole products should be consulted for specific recommendations regarding concomitant use with CYP450 3A4 inducers.', 'Metabolism', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, More', 'Acalabrutinib, Tepotinib, Avapritinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Axitinib, Ripretinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237198/', '[1] "Product Information. Abilify (ARIPiprazole)." Bristol-Myers Squibb  (2022):[2] "Product Information. Abilify Maintena (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2023):[3] "Product Information. Aristada (ARIPiprazole)." Alkermes, Inc  (2022):[4] "Product Information. Aristada Initio (ARIPiprazole)." Alkermes, Inc  (2022):[5] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[6] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceutical Co Ltd  (2021):[7] "Product Information. Abilify (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2023):[8] "Product Information. Abilify Maintena (aripiprazole)." Otsuka Pharmaceuticals (U.K.) Ltd  (2022):[9] "Product Information. Abilify (ARIPiprazole)." Otsuka Australia Pharmaceutical Pty Ltd  (2022):[10] "Product Information. Abilify Maintena (ARIPiprazole)." Lundbeck Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236637, 'Abiraterone', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Apalutamide, Exemestane', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237204/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236638, 'Abiraterone', 'Celecoxib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of celecoxib should be considered.', NULL, 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.', NULL, 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.  Dosage adjustments may be required if an interaction is suspected.  Patients should be advised to notify their physician if they experience potential signs and symptoms of celecoxib toxicity such as abdominal pain, black or tarry stools, nausea, vomiting, lethargy, fluid retention, swelling of legs, and worsening heart failure.', 'Metabolism', 'Darolutamide, Abarelix, Relugolix, Degarelix, Nilutamide, Aminoglutethimide', 'Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Opium, Ibuprofen, Pentazocine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237208/', '[1] "Product Information. Celebrex (celecoxib)." Searle  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236639, 'Abiraterone', 'Morphine', 'Major', 'Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including hypotension, respiratory and CNS depression, profound sedation, coma, and death.  The proposed mechanism may involve inhibition of the intestinal P-gp efflux transporter, resulting in enhanced oral bioavailability of morphine, a P-gp substrate.  The interaction may be more significant for orally administered morphine.  According to some authorities, the concomitant use of a P-gp inhibitor with oral morphine may increase the systemic exposure of morphine by approximately 2-fold.', NULL, 'Caution is recommended whenever morphine, particularly orally administered morphine, is used concomitantly with a P-gp inhibitor.', NULL, 'Caution is recommended whenever morphine, particularly orally administered morphine, is used concomitantly with a P-gp inhibitor.  Close clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy, and the morphine dosage adjusted as necessary.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation that may be greater than otherwise expected.  In addition, patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them.', 'Absorption', 'Darolutamide, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, Aminoglutethimide', 'Opium, Diphenoxylate, Difenoxin, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237220/', '[1] "Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):[2] "Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):[3] Kharasch ED, Hoffer C, Whittington D, Sheffels P "Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine." Clin Pharmacol Ther 74 (2003):  543-54[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Meissner K, Avram MJ, Yermolenka V, Francis AM, Blood J, Kharasch ED "Cyclosporine-inhibitable Blood-Brain Barrier Drug Transport Influences Clinical Morphine Pharmacodynamics." Anesthesiology  (2013):[7] Heiskanen T, Backman JT, Neuvonen M, Kontinen VK, Neuvonen PJ, Kalso E "Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine." Acta Anaesthesiol Scand 52 (2008):  1319-26', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236640, 'Ethanol', 'Posaconazole', 'Moderate', 'Concomitant use of alcohol and posaconazole administered in the form of delayed-release oral suspension may lead to a faster release of posaconazole.', NULL, 'MANAGEMENT Administration of posaconazole as delayed-release oral suspension with alcohol is not recommended.', NULL, 'MANAGEMENT Administration of posaconazole as delayed-release oral suspension with alcohol is not recommended.', 'Absorption', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More', 'Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237248/', '[1] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236641, 'Ethanol', 'Sulfamethoxazole', 'Moderate', 'First-generation sulfonylureas have been reported to cause facial flushing when administered with alcohol by inhibiting acetaldehyde dehydrogenase and subsequently causing acetaldehyde accumulation.  Since sulfamethoxazole is chemically related to first-generation sulfonylureas, a disulfiram-like reaction with products containing sulfamethoxazole is theoretically possible.', NULL, 'Patients should be alerted to the potential for this interaction and although the risk for this interaction is minimal, caution is recommended while taking sulfamethoxazole-trimethoprim concomitantly with alcohol.', NULL, 'Patients should be alerted to the potential for this interaction and although the risk for this interaction is minimal, caution is recommended while taking sulfamethoxazole-trimethoprim concomitantly with alcohol.', 'Metabolism', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Rifapentine, Streptomycin, Rifampicin, Rifabutin, Ethambutol, Pyridoxine, Pretomanid, Aminosalicylic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237252/', '[1] Heelon MW, White M "Disulfiram-cotrimoxazole reaction." Pharmacotherapy 18 (1998):  869-70[2] Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA "Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions." Antimicrob Agents Chemother 64 (2020):  e02167-19', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236642, 'Haloperidol', 'Botulinum toxin type A', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237255/', '[1] "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals[2] "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc[3] "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc[4] "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):[5] "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.  (2022):[6] "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236643, 'Botulinum toxin type A', 'Botulinum toxin type A', 'Moderate', 'The effect of administering different botulinum neurotoxin serotypes concurrently or within several months of one another is unknown.  Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237256/', '[1] "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals[2] "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc[3] "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc[4] "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):[5] "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.  (2022):[6] "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236644, 'Botulinum toxin type B', 'Botulinum toxin type A', 'Moderate', 'The effect of administering different botulinum neurotoxin serotypes concurrently or within several months of one another is unknown.  Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', NULL, 'Due to their similar pharmacologic profiles, the potential for additive neuromuscular blocking effects and paralysis should be considered.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237257/', '[1] "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals[2] "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc[3] "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc[4] "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):[5] "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.  (2022):[6] "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236645, 'Bacillus calmette-guerin substrain tice live antigen', 'Paclitaxel (protein-bound)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237262/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236646, 'Entrectinib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237267/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236647, 'Paclitaxel (protein-bound)', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237294/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236648, 'Paclitaxel', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237295/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp"   (2006):[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236649, 'Paclitaxel (protein-bound)', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237297/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236650, 'Pazopanib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration of substrates of CYP450 3A4, 2D6, or 2C8 with pazopanib may increase their plasma concentrations.  The mechanism is inhibition of CYP450-mediated metabolism by pazopanib.', NULL, 'Due to the potential for adverse effects, the concomitant use of pazopanib with drugs that have narrow therapeutic ranges and that are substrates of CYP450 3A4, 2D6, or 2C8 is not recommended.', NULL, 'Due to the potential for adverse effects, the concomitant use of pazopanib with drugs that have narrow therapeutic ranges and that are substrates of CYP450 3A4, 2D6, or 2C8 is not recommended.', 'Metabolism', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237298/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Votrient (pazopanib)." GlaxoSmithKline  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236651, 'Pralsetinib', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Acalabrutinib, Dacomitinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237308/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236652, 'Selinexor', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Aflibercept, Anagrelide, Panobinostat, Venetoclax, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237330/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp"   (2006):[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236653, 'Troglitazone', 'Paclitaxel (protein-bound)', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.', NULL, 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', NULL, 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', 'Metabolism', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237342/', '[1] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[2] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[3] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[6] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[11] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[12] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[13] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236654, 'Yellow Fever Vaccine', 'Paclitaxel (protein-bound)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237349/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236655, 'Varicella Zoster Vaccine (Recombinant)', 'Paclitaxel (protein-bound)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237350/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236656, 'Adalimumab', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237356/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236657, 'Adalimumab', 'Lisocabtagene maraleucel', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237378/', '[1] "Product Information. Remicade (infliximab)." Centocor Inc  (2001):[2] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories  (2001):[3] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):[4] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):[5] "Product Information. Simponi (golimumab)." Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm"   (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236658, 'Adalimumab', 'Melphalan flufenamide', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237381/', '[1] "Product Information. Remicade (infliximab)." Centocor Inc  (2001):[2] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories  (2001):[3] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):[4] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):[5] "Product Information. Simponi (golimumab)." Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm"   (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236659, 'Adalimumab', 'Promazine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescent and young adult males receiving treatment for Crohn''s disease or ulcerative colitis.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.  TNF blocker therapy should be discontinued if a serious infection or sepsis occurs.  Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237398/', '[1] "Product Information. Remicade (infliximab)." Centocor Inc  (2001):[2] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories  (2001):[3] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):[4] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):[5] "Product Information. Simponi (golimumab)." Centocor Inc  (2009):[6] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria.  http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm"   (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236660, 'Adalimumab', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237438/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236661, 'Adalimumab', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237439/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236662, 'Isotretinoin', 'Drospirenone', 'Moderate', 'Isotretinoin may decrease the plasma concentrations of contraceptive progestins.  The potential mechanism of interaction has not been established.', NULL, 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.', NULL, 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.  Combination oral contraceptive pills are considered an acceptable primary form of contraception and may be used (please refer to the product labeling for list of acceptable primary and secondary forms of contraception).  Due to the teratogenic risk of isotretinoin, females of reproductive potential must use two methods of effective contraception, at least one of which must be a primary form, for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month after discontinuing therapy.', 'Others', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Etonogestrel, More', 'Minocycline, Clindamycin, Vitamin A, Dexamethasone, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237845/', '[1] "Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):[2] Hendrix CW, Jackson KA, Whitmore E, et al. "The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone." Clin Pharmacol Ther 75 (2004):  464-75', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236663, 'Isotretinoin', 'Levonorgestrel', 'Moderate', 'Isotretinoin may decrease the plasma concentrations of contraceptive progestins.  The potential mechanism of interaction has not been established.', NULL, 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.', NULL, 'The manufacturers caution that microdosed progesterone-only preparations ("minipills") may not be an adequate method of contraception during isotretinoin therapy and should not be used.  Combination oral contraceptive pills are considered an acceptable primary form of contraception and may be used (please refer to the product labeling for list of acceptable primary and secondary forms of contraception).  Due to the teratogenic risk of isotretinoin, females of reproductive potential must use two methods of effective contraception, at least one of which must be a primary form, for at least 1 month prior to initiation of isotretinoin therapy, during therapy, and for 1 month after discontinuing therapy.', 'Others', 'Minocycline, Clindamycin, Vitamin A, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, Azelaic acid, Adapalene', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237850/', '[1] "Product Information. Accutane (isotretinoin)." Roche Laboratories  (2001):[2] Hendrix CW, Jackson KA, Whitmore E, et al. "The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone." Clin Pharmacol Ther 75 (2004):  464-75', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236664, 'Isotretinoin', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Minocycline, Clindamycin, Vitamin A, Fluorometholone, Azelaic acid, Adapalene', 'Entrectinib, Imatinib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237856/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236665, 'Fentanyl', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Azelastine, Ketotifen, Terfenadine, Astemizole', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ketamine, Naltrexone, Acetaminophen, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237860/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236666, 'Fentanyl', 'Berotralstat', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme.  Increased fentanyl concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease fentanyl plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to fentanyl.', NULL, 'Patients receiving fentanyl with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.', NULL, 'Patients receiving fentanyl with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.  This is particularly important when an inhibitor is added after a stable dose of fentanyl has been achieved.  Some authorities recommend avoiding concomitant use of fentanyl during and for 2 weeks after treatment with itraconazole.  Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath.  When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.  Patients treated with transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', 'Metabolism', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Halothane, Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237866/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):[2] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[3] "Product Information. Actiq (fentanyl)." Abbott Pharmaceutical  (2001):[4] Ibrahim AE, Feldman J, Karim A, Kharasch ED "Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil." Anesthesiology 98 (2003):  853-861[5] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M "Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation." Anesth Analg 82 (1996):  167-72[6] Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997):  1072-80[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236667, 'Fentanyl', 'Dextromethorphan', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Benzonatate, Dalfampridine, Inotersen, Tafamidis', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Acetylsalicylic acid, Acetaminophen, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237871/', '[1] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992):  235-6[6] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990):  48-50[10] "Product Information. Zoloft (sertraline)." Roerig Division  (2001):[11] "Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):[12] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982):  954-5[14] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):[16] "Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):[17] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994):  593-7[19] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):[20] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994):  983-5[21] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995):  428-9[25] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997):  287-9[31] "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):[32] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[33] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998):  432-6[35] "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):[36] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999):  156-8[42] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[43] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000):  134-8[46] "Product Information. Zyvox (linezolid)." Pharmacia and Upjohn  (2001):[47] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000):  254-6[48] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996):  1086-9[50] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002):  248-9[59] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001):  258-60[62] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003):  1197[66] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002):  401[67] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004):  111-3[74] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007):  199-202[90] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008):  521-5[92] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):[93] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009):  638-9[95] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med  (2012):[97] "Product Information. Oleptro (trazodone)." Labopharm Inc  (2012):[98] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):[99] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236668, 'Fentanyl', 'Ergotamine', 'Major', 'Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John''s wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.', NULL, 'In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.', 'Synergism', 'Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237874/', '[1] Hansen TE, Dieter K, Keepers GA "Interaction of fluoxetine and pentazocine." Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A "Interaction between fluoxetine and buspirone." Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M "Serotonin syndrome from trazodone and buspirone." Psychosomatics 33 (1992):  235-6[6] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990):  48-50[10] "Product Information. Zoloft (sertraline)." Roerig Division  (2001):[11] "Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):[12] Noble WH, Baker A "MAO inhibitors and coronary artery surgery: a patient death." Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL "Possible development of the serotonin syndrome in man." Am J Psychiatry 139 (1982):  954-5[14] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman''s the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.  (1990):[16] "Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):[17] "Product Information. Flexeril (cyclobenzaprine)." Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ "Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction." Anesth Analg 78 (1994):  593-7[19] "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome  (2001):[20] Ruiz F "Fluoxetine and the serotonin syndrome." Ann Emerg Med 24 (1994):  983-5[21] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA "Serotonin syndrome produced by paroxetine and low-dose trazodone." Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D "Serotonin syndrome from fluvoxamine and buspirone." Can J Psychiatry 40 (1995):  428-9[25] Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS "Possible serotonin syndrome with trazodone addition to fluoxetine." Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM "The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease." Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH "Possible serotonin syndrome associated with tramadol and sertraline coadministration." Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG "Serotonin syndrome associated with nefazodone and paroxetine." Ann Emerg Med 29 (1997):  287-9[31] "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals  (2001):[32] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[33] Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998):  432-6[35] "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc  (2001):[36] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC "Serotonin syndrome attributed to tramadol addition to paroxetine therapy." Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL "Meperidine as a potential cause of serotonin syndrome in the emergency department." Acad Emerg Med 6 (1999):  156-8[42] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[43] Gordon JB "SSRI''s and St. John''s Wort: possible toxicity?" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V "St. John''s wort and antidepressant drug interactions in the elderly." J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000):  134-8[46] "Product Information. Zyvox (linezolid)." Pharmacia and Upjohn  (2001):[47] Perry NK "Venlafaxine-induced serotonin syndrome with relapse following amitriptyline." Postgrad Med J 76 (2000):  254-6[48] Manos GH "Possible serotonin syndrome associated with buspirone added to fluoxetine." Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996):  1086-9[50] Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G "Serotonin syndrome from addition of low-dose trazodone to nefazodone." Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD "Antidepressants and the serotonin syndrome in general practice." Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG "A case report of serotonin syndrome associated with combined nefazodone and fluoxetine." J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL "Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient." J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J "Serotonin syndrome and atypical antipsychotics." Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB "Serotonin syndrome and linezolid." Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A "Linezolid: MAOI Activity and Potential Drug Interactions." Psychosomatics 43 (2002):  248-9[59] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T "Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine." Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ "Possible serotonin syndrome in association with 5-HT3 antagonist agents." Psychosomatics 42 (2001):  258-60[62] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR "Linezolid and serotonin syndrome." Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P "Serotonin syndrome after concomitant treatment with linezolid and citalopram." Clin Infect Dis 36 (2003):  1197[66] Dannawi M "Possible serotonin syndrome after combination of buspirone and St John''s Wort." J Psychopharmacol 16 (2002):  401[67] Tissot TA "Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use." Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I "Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients." Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK "Linezolid and serotonin toxicity." Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP "Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine." Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O''Brien D "Serotonin syndrome due to co-administration of linezolid and venlafaxine." J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N "Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram." J Am Med Dir Assoc 5 (2004):  111-3[74] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd "Serotonin syndrome and linezolid." J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H "Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine." Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S "Linezolid-associated serotonin syndrome: what we can learn from cases reported so far." J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA "Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient." J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E "Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL "Linezolid and serotonergic drug interactions: a retrospective survey." Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P "Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine." J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs." Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S "Rare case of serotonin syndrome with therapeutic doses of paroxetine." Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK "Mild serotonin syndrome associated with concurrent linezolid and fluoxetine." Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA "Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid." Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ "The serotonin syndrome, triptans, and the potential for drug-drug interactions." Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR "Serotonin syndrome caused by interaction between citalopram and fentanyl." J Clin Pharm Ther 32 (2007):  199-202[90] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C "Serotonin toxicity caused by an interaction between fentanyl and paroxetine." Can J Anaesth 55 (2008):  521-5[92] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):[93] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW "Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine." Psychosomatics 50 (2009):  638-9[95] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM "Serotonin Syndrome Associated With MDPV Use: A Case Report." Ann Emerg Med  (2012):[97] "Product Information. Oleptro (trazodone)." Labopharm Inc  (2012):[98] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):[99] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236669, 'Fentanyl', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Naltrexone, Acetaminophen, Ibuprofen, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237883/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236670, 'Fentanyl', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Halothane, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237887/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236671, 'Fentanyl', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More', 'Dalfampridine, Inotersen, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237896/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC  (2019):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236672, 'Fentanyl', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Oxymorphone, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237897/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236673, 'Fentanyl', 'Tolevamer', 'Moderate', 'Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.', NULL, 'Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.', NULL, 'Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.', 'Synergism', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237899/', '[1] Foresti V "Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate." Clin Nephrol 41 (1994):  252[2] "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236674, 'Acalabrutinib', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237913/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236675, 'Acalabrutinib', 'Berotralstat', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.', NULL, 'The dosage of acalabrutinib should be reduced to 100 mg once daily when coadministered with moderate CYP450 3A4 inhibitors.', 'Metabolism', 'Copanlisib, Lenvatinib, Erdafitinib, Dabrafenib, Abemaciclib, Vandetanib, Trametinib, Dacomitinib, Alectinib, Binimetinib', 'Betibeglogene autotemcel, Hyaluronidase, Lanadelumab, Human C1-esterase inhibitor, Crizanlizumab, Conestat alfa, Icatibant', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237915/', '[1] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236676, 'Acalabrutinib', 'Heparin (flush)', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', NULL, 'Caution and monitoring (e.', NULL, 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More', 'Protein C, Acenocoumarol, Selexipag, Ascorbic acid, Sirolimus, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237926/', '[1] Passannante A, Macik BG "The heparin flush syndrome: a cause of iatrogenic hemorrhage." Am J Med Sci 296 (1988):  71-3[2] "Product Information. Heparin Sodium in Sodium Chloride (heparin flush)." Baxter Healthcare Corporation  (2022):[3] "Product Information. Canusal (heparin flush)." Wockhardt UK Ltd  (2018):[4] "Product Information. Heparinised Saline (Pfizer) (heparinised saline)." Pfizer Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236677, 'Acalabrutinib', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Copanlisib, Abemaciclib, Erdafitinib, Neratinib, Erlotinib, Pralsetinib, Dacomitinib, Alectinib, Binimetinib', 'Acalabrutinib, Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237958/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236678, 'Acalabrutinib', 'Sunitinib', 'Major', 'Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', NULL, 'Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.', NULL, 'Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.  Close clinical and laboratory monitoring for bleeding complications is recommended during therapy.  Patients should be advised to promptly report any signs and symptoms of bleeding to their physician.', 'Synergism', 'Imatinib, Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, Sunitinib, Ripretinib, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Axitinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237983/', '[1] "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236679, 'Acalabrutinib', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237993/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236680, 'Acalabrutinib', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Entrectinib, Pralsetinib, Dabrafenib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Larotrectinib, Vemurafenib, Lapatinib, Selumetinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/237994/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236681, 'Daclatasvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Guar gum', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238054/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236682, 'Fluocinolone acetonide', 'Acarbose', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Fluorometholone, Hydrocortisone butyrate, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238056/', '[1] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42[2] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993):  84-7[3] Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522[4] Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim[5] "Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):[6] "Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):[7] "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome[8] "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236683, 'Simeprevir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Guar gum', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238065/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236684, 'Sofosbuvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Simvastatin, Guar gum, Rosuvastatin', 'Lamivudine, Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238067/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236685, 'Clonazepam', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Lacosamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238070/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236686, 'Clonazepam', 'Chlorcyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Oxcarbazepine, Ethotoin, Methsuximide, Paramethadione, Carbamazepine, Phensuximide, Fosphenytoin, Methylphenobarbital, Phenacemide, Phenytoin, Felbamate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238079/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236687, 'Clonazepam', 'Chlormezanone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Lacosamide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238080/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236688, 'Cyclizine', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Methsuximide, Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Trimethadione, Lacosamide', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238081/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236689, 'Dimenhydrinate', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Lacosamide', 'Ketotifen, Dexchlorpheniramine, Astemizole, Azelastine, Terfenadine, Pheniramine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238085/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236690, 'Felbamate', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Paramethadione, Phensuximide, Methylphenobarbital, Phenacemide, Felbamate, Lacosamide, Trimethadione', 'Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238088/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236691, 'Fenfluramine', 'Clonazepam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Lacosamide, Fenfluramine', 'Dexfenfluramine, Ephedrine, Lorcaserin, Diethylpropion, Mazindol, Clonazepam, Methsuximide, Paramethadione, Phensuximide, Phenacemide, Trimethadione, Lacosamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238089/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236692, 'Clonazepam', 'Methyldopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Topiramate, Ezogabine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, Paramethadione, Carbamazepine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238098/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236693, 'Clonazepam', 'Osilodrostat', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Ethotoin, Brivaracetam, Gabapentin, Valproic acid, Topiramate, Paramethadione, Methsuximide, Perampanel, Phensuximide, Lamotrigine, Phenacemide, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238103/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc  (2020):[2] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Australia Pty Ltd  (2022):[3] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases UK Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236694, 'Clonazepam', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Brivaracetam, Topiramate, Lamotrigine, Methylphenobarbital, Levetiracetam, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Vigabatrin, More', 'Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Ribociclib, Vandetanib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238106/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236695, 'Clonazepam', 'Remimazolam', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Lacosamide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238108/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236696, 'Bromocriptine', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine.  Orally administered bromocriptine is extensively metabolized in the gastrointestinal tract and liver by CYP450 3A4, with approximately 93% of the absorbed dose undergoing first-pass metabolism and only the remaining 7% reaching systemic circulation.  As such, inhibitors of CYP450 3A4 may markedly reduce the metabolic clearance of bromocriptine.', NULL, 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', NULL, 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', 'Metabolism', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, Safinamide, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238118/', '[1] Nelson MV, Berchou RC, Kareti D, Le Witt PA "Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine." Clin Pharmacol Ther 47 (1990):  694-7[2] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation  (2001):[3] von Rosenstiel NA, Adam D "Macrolide antibacterials. Drug interactions of clinical significance." Drug Saf 13 (1995):  105-22[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Periti P, Mazzei T, Mini E, Novelli A "Pharmacokinetic drug interactions of macrolides." Clin Pharmacokinet 23 (1992):  106-31[7] "Product Information. Cycloset (bromocriptine)." Valeant Pharmaceuticals  (2018):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236697, 'Drospirenone', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', NULL, 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', NULL, 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, More', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, Bromotheophylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238121/', '[1] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation  (2011):[2] "Product Information. Slynd (drospirenone)." Exeltis USA, Inc.  (2022):[3] "Product Information. Angeliq (drospirenone-estradiol)." Bayer Pharmaceutical Inc  (2017):[4] "Product Information. Slinda (drospirenone)." Besins Healthcare Australia Pty Ltd  (2021):[5] "Product Information. Angeliq 1/2 (drospirenone-estradiol)." Bayer Australia Limited  (2021):[6] "Product Information. Slynd (drospirenone)." Duchesnay Inc  (2021):[7] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb  (2022):[8] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236698, 'Fedratinib', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fedratinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19 and flavin-containing monooxygenase 3 (FMO3).', NULL, 'Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.', NULL, 'Caution is advised when fedratinib is used with CYP450 3A4 inhibitors, particularly those that may also inhibit CYP450 2C19 (e.g., amiodarone, cimetidine, fexinidazole, isoniazid, osilodrostat, rucaparib) or if combined with other drugs that can inhibit CYP450 2C19 (e.g., esomeprazole, fenofibrate, fluoxetine, lansoprazole, letrozole, moclobemide, omeprazole, parecoxib, ticlopidine).  Patients should be monitored for adverse reactions such as nausea, vomiting, diarrhea, anemia, thrombocytopenia, neutropenia, encephalopathy (including Wernicke''s), liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations, increased blood creatinine, and secondary malignancies.  Dosage adjustment or treatment interruption may be required based on patient tolerance and response in accordance with the prescribing information.', 'Metabolism', 'Dacomitinib, Pacritinib, Vemurafenib, Vandetanib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, Encorafenib, Sunitinib, Regorafenib, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238122/', '[1] Wu F, Krishna G, Surapaneni S "Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib." Cancer Chemother Pharmacol 86 (2020):  461-73[2] "Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb  (2022):[3] "Product Information. Inrebic (fedratinib)." Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236699, 'Zafirlukast', 'Selinexor', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Niraparib, More', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238133/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp"   (2006):[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236700, 'Somatotropin', 'Astemizole', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238140/', '[1] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company  (2003):[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236701, 'Bepridil', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238144/', '[1] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company  (2003):[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236702, 'Bromocriptine', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bromocriptine.', NULL, 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of bromocriptine should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238146/', '[1] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Cycloset (bromocriptine)." Valeant Pharmaceuticals  (2018):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236703, 'Somatotropin', 'Pitolisant', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238167/', '[1] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company  (2003):[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236704, 'Tramadol', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tramadol, which is primarily metabolized by CYP450 3A4 and 2D6.  Reduced opioid efficacy can occur, including opioid withdrawal in physically dependent patients.', NULL, 'Caution is advised when tramadol is used with CYP450 3A4 inducers.', NULL, 'Caution is advised when tramadol is used with CYP450 3A4 inducers.  Patients should be monitored for opioid efficacy and signs of withdrawal.  If a CYP450 3A4 inducer is discontinued, monitor for seizures, serotonin syndrome, sedation, and respiratory depression.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 'Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238174/', '[1] "Product Information. Seglentis (celecoxib-tramadol)." Kowa Pharmaceuticals America (formerly ProEthic)  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236705, 'Aminosalicylic acid', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238261/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236706, 'Amyl Nitrite', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Tripelennamine, Clemastine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, Amiodarone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238262/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236707, 'Bupivacaine', 'Lidocaine', 'Major', 'Additive toxicities may occur when bupivacaine is coadministered with other local anesthetics.  The potential for increased risk of systemic toxicities such as methemoglobinemia and central nervous system and cardiovascular adverse reactions should be recognized.', NULL, 'Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine.', NULL, 'Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine.  If coadministration cannot be avoided, overall local anesthetic exposure through 72 hours must be considered in addition to monitoring for the development of methemoglobinemia as well as central nervous system and cardiovascular adverse reactions.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Early warning signs of central nervous system toxicity may include restlessness, anxiety, incoherent speech, dizziness, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, blurred vision, tremors, twitching, depression, and drowsiness.  Cardiovascular toxicity may include atrioventricular block, ventricular arrhythmias, cardiac arrest, and decreased cardiac output and arterial blood pressure due to depressed cardiac conductivity, excitability, and myocardial contractility.  Patients should have cardiovascular and respiratory vital signs and state of consciousness constantly monitored while under treatment.', 'Synergism', 'Lidocaine, Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Procaine, Articaine, Etidocaine', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238264/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236708, 'Chloroquine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238266/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236709, 'Dapsone', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238267/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236710, 'Dapsone (topical)', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238268/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236711, 'Eslicarbazepine', 'Lidocaine', 'Moderate', 'There is clinical evidence that eslicarbazepine acetate can prolong the PR interval of the electrocardiogram (ECG) in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, lopinavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular (AV) block.', NULL, 'Caution is advised if eslicarbazepine is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.', NULL, 'Caution is advised if eslicarbazepine is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block; second-degree or higher AV block; sick sinus syndrome without pacemaker), or a history of syncope, arrhythmia or severe cardiac disease such as myocardial ischemia or heart failure.  Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Ropivacaine, Chloroprocaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238269/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236712, 'Flutamide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Darolutamide, Anastrozole, Fulvestrant, Toremifene, Abarelix, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238272/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236713, 'Hydroxyurea', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238274/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236714, 'Ifosfamide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More', 'Flurbiprofen, Chlorhexidine, Povidone-iodine, Quinidine, Amiodarone, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238275/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236715, 'Isosorbide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238277/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236716, 'Isosorbide dinitrate', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, More', 'Tripelennamine, Clemastine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Dronedarone, Tocainide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238278/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236717, 'Isosorbide mononitrate', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Nesiritide, Vericiguat', 'Tripelennamine, Clemastine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Tocainide, Dronedarone, Procainamide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238279/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236718, 'Lidocaine (ophthalmic)', 'Lidocaine', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Lidocaine, Procaine, Tetracaine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Lidocaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238281/', '[1] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001):  150-3[2] "Product Information. Hurricaine (benzocaine topical)." Beutlich  (2005):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[7] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech)  (2020):[8] "Product Information. Diclona (diclofenac-lidocaine topical)." Terrain Pharmaceuticals  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236719, 'Lidocaine', 'Lidocaine (topical)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Lidocaine, Procaine, Tetracaine, Lidocaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Lidocaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238282/', '[1] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001):  150-3[2] "Product Information. Hurricaine (benzocaine topical)." Beutlich  (2005):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[7] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech)  (2020):[8] "Product Information. Diclona (diclofenac-lidocaine topical)." Terrain Pharmaceuticals  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236720, 'Metoclopramide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Pheniramine, Flurbiprofen, Povidone-iodine, Bacitracin, Propafenone, Tocainide, Mexiletine, Bretylium, Moricizine, Ibutilide, Zinc sulfate, More', 'Cisapride', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238285/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236721, 'Morphine', 'Lidocaine', 'Moderate', 'Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.', NULL, 'To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.', NULL, 'To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.', 'Absorption', 'Procaine, Tetracaine, Tetracaine, Flurbiprofen, Povidone-iodine, Tocainide, Procainamide, Disopyramide, Bretylium, Moricizine, Ibutilide, More', 'Opium, Eluxadoline, Diphenoxylate, Difenoxin, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Opium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238290/', '[1] "Product Information. DepoDur (morphine liposomal)." Endo Laboratories LLC  (2004):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236722, 'Nitric Oxide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, More', 'Doxapram, Elexacaftor', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238292/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236723, 'Nitrofurantoin', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238293/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236724, 'Nitroglycerin', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Tripelennamine, Clemastine, Pheniramine, Neomycin, Flurbiprofen, Povidone-iodine, Bacitracin, Propafenone, Dronedarone, Tocainide, Procainamide, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238294/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236725, 'Nitroprusside', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Tripelennamine, Clemastine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, Amiodarone, More', 'Minoxidil, Diazoxide, Hydralazine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238295/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236726, 'Nitrous oxide', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Thiopental, Sodium oxybate, Methohexital, Enflurane, Esketamine, Halothane', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238296/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236727, 'Phenazopyridine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Apomorphine, Fesoterodine, Pentosan polysulfate, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Avanafil, Papaverine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238299/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236728, 'Pralsetinib', 'Lidocaine', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238301/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236729, 'Primaquine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238302/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236730, 'Quinine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238304/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236731, 'Rasburicase', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238305/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236732, 'Silver nitrate (topical)', 'Lidocaine', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238307/', '[1] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT "Acquired methemoglobinemia." West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M "Severe methemoglobinaemia due to benzocaine-containing ''burn cream'': two case reports in an adult and in a child." Burns 37 (2011):  e63-6[4] Gala HC, Madave A "An unusual case of neonatal methemoglobinemia." Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a "Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center''s four-year experience." J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R "Topical antimicrobial agents for pediatric burns." Burns Trauma 5 (2017):  33', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236733, 'Silver sulfadiazine (topical)', 'Lidocaine', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238308/', '[1] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT "Acquired methemoglobinemia." West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M "Severe methemoglobinaemia due to benzocaine-containing ''burn cream'': two case reports in an adult and in a child." Burns 37 (2011):  e63-6[4] Gala HC, Madave A "An unusual case of neonatal methemoglobinemia." Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a "Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center''s four-year experience." J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R "Topical antimicrobial agents for pediatric burns." Burns Trauma 5 (2017):  33', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236734, 'Sulfadiazine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, More', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Ketoconazole, Probenecid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238310/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236735, 'Sulfamethizole', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Magnesium citrate, Sodium chloride, Sorbitol, Sodium citrate, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Lactic acid, Methazolamide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238311/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236736, 'Sulfamethoxazole', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Moricizine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Tinidazole, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238312/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236737, 'Sulfisoxazole', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Ketoconazole, Probenecid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238313/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236738, 'Tafenoquine', 'Lidocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238314/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236739, 'Salbutamol', 'Ketamine', 'Moderate', 'Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.', NULL, 'Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.', NULL, 'Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient''s clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.', 'Synergism', 'Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine', 'Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238326/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ketalar (ketamine)." JHP Pharmaceuticals  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236740, 'Salbutamol', 'Pralsetinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Ephedrine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238334/', '[1] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71[2] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9[3] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9[4] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20[6] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9[7] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6[8] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990):  575-9[9] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5[10] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32[11] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6[12] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9[13] "Product Information. Proventil (albuterol)." Schering Corporation  (2002):[14] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61[15] "Product Information. Serevent (salmeterol)." Glaxo Wellcome[16] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):[17] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994):  729-33[18] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9[19] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75[20] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7[21] "Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):[22] "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):[23] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003):  1817-24[24] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006):  582-90[25] "Product Information. Brovana (arformoterol)." Sepracor Inc  (2006):[26] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001):  45-51[27] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998):  1400-5[28] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals  (2011):[29] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline  (2013):[30] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236741, 'Dexmethylphenidate', 'Quinapril', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238348/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236742, 'Hydralazine', 'Quinapril', 'Moderate', 'Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', 'Synergism', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238355/', '[1] "Product Information. Apresoline (hydralazine)." Sterimax Inc  (2022):[2] "Product Information. Hydralazine (hydralazine)." Advanz Pharma  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236743, 'Dexmethylphenidate', 'Acebutolol', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238385/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236744, 'Eslicarbazepine', 'Acebutolol', 'Moderate', 'There is clinical evidence that eslicarbazepine acetate can prolong the PR interval of the electrocardiogram (ECG) in some patients.  Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, lopinavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular (AV) block.', NULL, 'Caution is advised if eslicarbazepine is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.', NULL, 'Caution is advised if eslicarbazepine is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block; second-degree or higher AV block; sick sinus syndrome without pacemaker), or a history of syncope, arrhythmia or severe cardiac disease such as myocardial ischemia or heart failure.  Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', 'Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238387/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc  (2013):[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236745, 'Hydralazine', 'Acebutolol', 'Moderate', 'Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', 'Synergism', 'Nebivolol, Nebivolol', 'Minoxidil, Nitroprusside, Diazoxide, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238393/', '[1] "Product Information. Apresoline (hydralazine)." Sterimax Inc  (2022):[2] "Product Information. Hydralazine (hydralazine)." Advanz Pharma  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236746, 'Acebutolol', 'Methylphenidate', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238400/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236747, 'Pyrophosphoric acid', 'Acebutolol', 'Moderate', 'Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.', NULL, 'Clinicians should be aware of the possibility of a diagnostic interference.', NULL, 'Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.', 'Distribution', 'Carteolol', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238407/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Pyrophosphate (pyrophosphate)." Pharmalucence Inc  (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236748, 'Remimazolam', 'Acebutolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Lemborexant, Methohexital, Estazolam, Zopiclone, Midazolam, Melatonin, Valerian', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238410/', '[1] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998):  595', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236749, 'Dexmethylphenidate', 'Perindopril', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil', 'Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238426/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236750, 'Hydralazine', 'Perindopril', 'Moderate', 'Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', 'Synergism', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Fenofibrate, Ezetimibe, Bempedoic acid, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238433/', '[1] "Product Information. Apresoline (hydralazine)." Sterimax Inc  (2022):[2] "Product Information. Hydralazine (hydralazine)." Advanz Pharma  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236751, 'Perindopril', 'Methylphenidate', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline, Modafinil', 'Bempedoic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238438/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236752, 'Budesonide', 'Acetazolamide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.  Potassium supplementation may be necessary.  Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Isoprenaline, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238454/', '[1] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984):  60-5[2] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42[3] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992):  312[4] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969):  425-32[5] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993):  2110-2[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966):  775-81[7] "Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):[8] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995):  656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236753, 'Acetazolamide', 'Mefloquine', 'Moderate', 'Mefloquine may increase the risk of seizures and decrease the effectiveness of anticonvulsant drugs in patients with epilepsy.', NULL, 'Because it can increase the risk of seizures in patients with epilepsy, mefloquine should only be used for curative treatment of malaria in such patients and only if there are compelling medical reasons for its use.', NULL, 'Because it can increase the risk of seizures in patients with epilepsy, mefloquine should only be used for curative treatment of malaria in such patients and only if there are compelling medical reasons for its use.  Patient clinical status and anticonvulsant blood levels should be closely monitored if mefloquine is prescribed.  Dosage adjustments may be required.  Patients should be advised to notify their physician if they experience a loss of seizure control.  Mefloquine should not be prescribed for malaria prophylaxis in patients with a history of convulsions.', 'Antagonism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238463/', '[1] Singh K, Shanks GD, Wilde H "Seizures after mefloquine." Ann Intern Med 114 (1991):  994[2] Weinke T, Trautmann M, Held T, et al. "Neuropsychiatric side effects after the use of mefloquine." Am J Trop Med Hyg 45 (1991):  86-91[3] Bem JL, Kerr L, Stuerchler D "Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions." J Trop Med Hyg 95 (1992):  167-79[4] "Product Information. Lariam (mefloquine)." Roche Laboratories  (2002):[5] Ries S, Pohlmanneden B "Seizures during malaria prophylaxis with mefloquine." Dtsch Med Wochenschr 118 (1993):  1911-2[6] Ruff TA, Sherwen SJ, Donnan GA "Seizure associated with mefloquine for malaria prophylaxis." Med J Aust 161 (1994):  453[7] Pous E, Gascon J, Obach J, Corachan M "Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject." Trans R Soc Trop Med Hyg 89 (1995):  434[8] Potasman I, Juven Y, Weller B, Schwartz E "Does mefloquine prophylaxis affect electroencephalographic patterns?" Am J Med 112 (2002):  147-9[9] Jimenez-Huete A, Gil-Nagel A, Franch O "Multifocal myoclonus associated with mefloquine chemoprophylaxis." Clin Neuropharmacol 25 (2002):  243', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236754, 'Acetazolamide', 'Pemoline', 'Moderate', 'Decreased seizure threshold has been reported in patients receiving pemoline concomitantly with antiepileptic medications.  The mechanism of interaction has not been described, although convulsive seizures have been reported as a side effect of pemoline.', NULL, 'Caution and clinical monitoring are advised when pemoline is used in patients receiving anticonvulsant therapy.', NULL, 'Caution and clinical monitoring are advised when pemoline is used in patients receiving anticonvulsant therapy.  Patients should be advised to notify their physician if they experience loss of seizure control.', 'Antagonism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Amphetamine, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline, Modafinil', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238465/', '[1] "Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236755, 'Famotidine', 'Pralsetinib', 'Moderate', 'Famotidine may cause QTc prolongation.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution and clinical monitoring are recommended if famotidine is used in combination with other drugs that can prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin', 'Tepotinib, Larotrectinib, Avapritinib, Fedratinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Duvelisib, Tivozanib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238509/', '[1] "Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236756, 'Sacituzumab govitecan', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238530/', '[1] Salminen MK, Rautelin H, Tynkkynen S, et al. "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr 83 (2006):  1256-64', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236757, 'Ozanimod', 'Lactulose', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238550/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Canadian Pharmacists Association "e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink"   (2006):[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998):  907-14', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236758, 'Pralsetinib', 'Lactulose', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.  The recommended dosage and duration of use should not be exceeded.  Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate', 'Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, Capmatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238554/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Canadian Pharmacists Association "e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink"   (2006):[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Schaefer DC, Cheskin LJ "Constipation in the elderly." Am Fam Physician 58 (1998):  907-14', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236759, 'Rabeprazole', 'Osilodrostat', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Lansoprazole, Ketoprofen, Diclofenac, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238576/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc  (2020):[2] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Australia Pty Ltd  (2022):[3] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases UK Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236760, 'Rabeprazole', 'Pemigatinib', 'Moderate', 'Coadministration of pemigatinib with proton pump inhibitors may result in a reduction in the plasma concentrations of pemigatinib.  The mechanism for this interaction has not been delineated.', NULL, 'Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.', NULL, 'Until more information is available, caution is recommended when pemigatinib is used concomitantly with proton pump inhibitors.  Patients should be monitored for potentially reduced efficacy.', 'Others', 'Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, Ribociclib, Cobimetinib, More', 'Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238577/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236761, 'Rabeprazole', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Entrectinib, Dabrafenib, Asciminib, Pacritinib, Tepotinib, Avapritinib, Larotrectinib, Vemurafenib, Selumetinib, Ribociclib, Cobimetinib, More', 'Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Fenoprofen, Meclofenamic acid, Ketorolac, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238579/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236762, 'Adefovir dipivoxil', 'Zoledronic acid', 'Moderate', 'Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents).  Renal function and serum electrolytes should be monitored.  Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.  In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238587/', '[1] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG "Effects of intravenous diphosphonates on renal function." Lancet 1 (1983):  1328[2] "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals  (2001):[3] Osullivan TL, Akbari A, Cadnapaphornchai P "Acute renal failure associated with the administration of parenteral etidronate." Ren Fail 16 (1994):  767-73[4] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M "Acute renal failure and alendronate." Nephrol Dial Transplant 12 (1997):  2797-8[5] "Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):[6] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D "Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases." Nephron 89 (2001):  467-8[7] Lockridge L, Papac RJ, Perazella MA "Pamidronate-associated nephrotoxicity in a patient with Langerhans''s histiocytosis." Am J Kidney Dis 40 (2002):  E2[8] Markowitz GS, Fine PL, Stack JI, et al. "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)." Kidney Int 64 (2003):  281-289[9] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003):  E18[10] Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003):  1676-9; discussion 1676-9[11] "Product Information. Ostac (clodronate)." Hoffmann-La Roche Limited  (2004):[12] "Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236763, 'Zoledronic acid', 'Moxetumomab Pasudotox', 'Moderate', 'Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents).  Renal function and serum electrolytes should be monitored.  Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.  In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238594/', '[1] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG "Effects of intravenous diphosphonates on renal function." Lancet 1 (1983):  1328[2] "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals  (2001):[3] Osullivan TL, Akbari A, Cadnapaphornchai P "Acute renal failure associated with the administration of parenteral etidronate." Ren Fail 16 (1994):  767-73[4] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M "Acute renal failure and alendronate." Nephrol Dial Transplant 12 (1997):  2797-8[5] "Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):[6] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D "Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases." Nephron 89 (2001):  467-8[7] Lockridge L, Papac RJ, Perazella MA "Pamidronate-associated nephrotoxicity in a patient with Langerhans''s histiocytosis." Am J Kidney Dis 40 (2002):  E2[8] Markowitz GS, Fine PL, Stack JI, et al. "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)." Kidney Int 64 (2003):  281-289[9] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003):  E18[10] Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003):  1676-9; discussion 1676-9[11] "Product Information. Ostac (clodronate)." Hoffmann-La Roche Limited  (2004):[12] "Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236764, 'Adefovir dipivoxil', 'Metformin', 'Moderate', 'Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Excretion', 'Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Cobicistat, Brincidofovir, Remdesivir, Doravirine, More', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Tolbutamide, Miglitol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238607/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236765, 'Fedratinib', 'Metformin', 'Moderate', 'Coadministration with fedratinib may decrease the renal clearance of drugs that are excreted via organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) 1/2-K.', NULL, 'Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.', NULL, 'Caution is advised when fedratinib is used with drugs that are renally excreted via OCT2, MATE1, and MATE2-K.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.', 'Excretion', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Miglitol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238612/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Inrebic (fedratinib)." Celgene Corporation  (2019):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236766, 'Fluocinolone acetonide', 'Metformin', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'Antagonism', 'Fluorometholone, Hydrocortisone butyrate, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Salicylic acid, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238614/', '[1] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42[2] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993):  84-7[3] Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522[4] Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim[5] "Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):[6] "Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):[7] "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome[8] "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236767, 'Pralsetinib', 'Metformin', 'Moderate', 'Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism, Excretion', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238627/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236768, 'Selpercatinib', 'Metformin', 'Minor', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the renal transporter multidrug and toxin extrusion protein 1 (MATE1).', NULL, 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the renal transporter multidrug and toxin extrusion protein 1 (MATE1).', NULL, 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are substrates of the renal transporter multidrug and toxin extrusion protein 1 (MATE1).  In vitro studies indicate that selpercatinib inhibits MATE1 at clinically relevant concentrations.  However, the clinical significance of this finding has not been established.  No clinically significant differences in glucose levels were observed when metformin, a MATE1 substrate, was coadministered with selpercatinib.', 'Excretion', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238628/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236769, 'Simeprevir', 'Metformin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Guar gum', 'Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Vemurafenib, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238629/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236770, 'Sofosbuvir', 'Metformin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Simvastatin, Guar gum, Rosuvastatin', 'Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Cobicistat, Brincidofovir, Remdesivir, Doravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238631/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236771, 'Acrivastine', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238636/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236772, 'Dronabinol', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nabilone, Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Granisetron, Dronabinol, Rolapitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238643/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236773, 'Fenfluramine', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide', 'Aprepitant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238645/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236774, 'Nabilone', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amantadine, Cabergoline', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238648/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236775, 'Nabilone', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nitrazepam, Zopiclone', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238649/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236776, 'Nabilone', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nitrazepam, Zopiclone, Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238650/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236777, 'Safinamide', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron', 'Amantadine, Cabergoline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238654/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236778, 'Scopolamine', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Granisetron, Scopolamine, Rolapitant, Aprepitant, Dolasetron, Palonosetron', 'Nitrazepam, Zopiclone, Ketorolac, Homatropine, Atropine, Ephedrine, Methscopolamine, Tropicamide, Phenylephrine, Nabilone, Granisetron, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238655/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236779, 'Selegiline', 'Nabilone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Granisetron, Rolapitant, Aprepitant, Dolasetron, Palonosetron', 'Amantadine, Cabergoline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238656/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236780, 'Amphotericin B (cholesteryl sulfate)', 'Risperidone', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Probenecid, Tioconazole, Brinzolamide, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238661/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236781, 'Amphotericin B (liposomal)', 'Risperidone', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, Probenecid, Tioconazole, Brinzolamide, More', 'Methotrimeprazine, Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Olanzapine, Aripiprazole, Loxapine, Molindone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238662/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236782, 'Darolutamide', 'Risperidone', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', 'Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant', 'Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Cariprazine, Mesoridazine, Pimavanserin, Clozapine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238672/', '[1] "Product Information. Lupron (leuprolide)." TAP Pharmaceuticals Inc  (2002):[2] "Product Information. Zoladex (goserelin)." Astra-Zeneca Pharmaceuticals  (2001):[3] "Product Information. Trelstar (triptorelin)." Pharmacia and Upjohn  (2001):[4] "Product Information. Eligard (leuprolide)." Sanofi Winthrop Pharmaceuticals  (2002):[5] "Product Information. Plenaxis (abarelix)." Praecis Pharmaceuticals Inc  (2003):[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc)  (2010):[8] "Product Information. Firmagon (degarelix)." Ferring Pharmaceuticals Inc  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236783, 'Dexmethylphenidate', 'Risperidone', 'Moderate', 'The coadministration of risperidone with serdexmethylphenidate, dexmethylphenidate, or methylphenidate, when there is an increase or decrease of dosage of either medication, may increase the risk of extrapyramidal symptoms.', NULL, 'Caution is advised if risperidone must be used concomitantly with methylphenidate, dexmethylphenidate, or serdexmethylphenidate.', NULL, 'Caution is advised if risperidone must be used concomitantly with methylphenidate, dexmethylphenidate, or serdexmethylphenidate.  Patients should be monitored more closely whenever either drug is added to or withdrawn from therapy and whenever either dosage is changed.  Patients should be monitored for the development of extrapyramidal symptoms (e.g., tremor, shuffling gait, drooling, mask-like face, tongue stiffness, muscle spasms or rigidity, involuntary movements) and changes in mental status.', 'Synergism', 'Pemoline, Solriamfetol, Caffeine, Dextroamphetamine, Armodafinil, Citicoline', 'Quetiapine, Asenapine, Thiothixene, Pimavanserin, Lumateperone, Clozapine, Ziprasidone, Olanzapine, Iloperidone, Amisulpride, Aripiprazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238674/', '[1] "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):[2] "Product Information. Risperdal Consta (risperidone)." Janssen Pharmaceuticals  (2005):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236784, 'Fenfluramine', 'Risperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Dexfenfluramine, Ephedrine, Diethylpropion, Mazindol, Lacosamide', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238679/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236785, 'Risperidone', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Thiopental, Ethchlorvynol, Dichloralphenazone', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238687/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236786, 'Risperidone', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Thiopental, Ethchlorvynol, Dichloralphenazone, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238688/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236787, 'Risperidone', 'Mitotane', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone.  Both risperidone and 9-hydroxyrisperidone are substrates of the CYP450 3A4 isoenzyme and P-gp efflux transporter.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.g., over 1 to 2 weeks) following the addition of a potent CYP450 3A4/P-gp inducer.  For extended-release injectable formulations of risperidone, patients should be closely monitored for the first 4 to 8 weeks after starting treatment with a potent CYP450 3A4/P-gp inducer.  A dosage increase or supplemental oral risperidone therapy may be required in some cases.  Changes in efficacy and safety should be carefully monitored with any dosage adjustment.  Upon discontinuation of the inducer, risperidone dosage should be reassessed and readjusted accordingly for the anticipated increase in plasma concentrations of risperidone and 9-hydroxyrisperidone.  The prescribing information for individual risperidone products should be consulted for specific recommendations regarding concomitant use with potent CYP450 3A4 inducers.', 'Metabolism', 'Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', 'Fluphenazine, Thiothixene, Amisulpride, Promazine, Prochlorperazine, Thioridazine, Pimozide, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238692/', '[1] "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):[2] Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E "Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate." Ther Drug Monit 22 (2000):  481-5[3] Spina E, Scordo MG, Avenoso A, Perucca E "Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity." J Clin Psychopharmacol 21 (2001):  108-9[4] "Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2022):[5] "Product Information. Perseris (risperiDONE)." Indivior Inc.  (2022):[6] "Product Information. RisperDAL Consta (risperiDONE)." Janssen Pharmaceuticals  (2021):[7] "Product Information. Teva-Risperidone (risperidone)." Teva Canada Limited  (2022):[8] "Product Information. Perseris (risperidone)." HLS Therapeutics Inc  (2021):[9] "Product Information. Risperdal Consta (risperidone)." Janssen Inc  (2020):[10] "Product Information. Rixadone (riSPERIDONe)." Alphapharm Pty Ltd  (2022):[11] "Product Information. Risperdal Consta (riSPERIDONe)." Janssen-Cilag Pty Ltd  (2020):[12] "Product Information. Risperidone (risperidone)." Krka UK Ltd  (2023):[13] "Product Information. Okedi (risperidone)." ROVI Biotech Ltd  (2022):[14] "Product Information. Risperdal Consta (risperidone)." Janssen-Cilag Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236788, 'Risperidone', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', NULL, 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dabrafenib, Acalabrutinib, Pexidartinib, Avapritinib, Bosutinib, Selumetinib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, Tivozanib, More', 'Amisulpride, Loxapine, Molindone, Thiothixene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238698/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236789, 'Risperidone', 'Rifampicin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone.  Both risperidone and 9-hydroxyrisperidone are substrates of the CYP450 3A4 isoenzyme and P-gp efflux transporter.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.g., over 1 to 2 weeks) following the addition of a potent CYP450 3A4/P-gp inducer.  For extended-release injectable formulations of risperidone, patients should be closely monitored for the first 4 to 8 weeks after starting treatment with a potent CYP450 3A4/P-gp inducer.  A dosage increase or supplemental oral risperidone therapy may be required in some cases.  Changes in efficacy and safety should be carefully monitored with any dosage adjustment.  Upon discontinuation of the inducer, risperidone dosage should be reassessed and readjusted accordingly for the anticipated increase in plasma concentrations of risperidone and 9-hydroxyrisperidone.  The prescribing information for individual risperidone products should be consulted for specific recommendations regarding concomitant use with potent CYP450 3A4 inducers.', 'Metabolism', 'Pyrazinamide, Rifamycin, Streptomycin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238700/', '[1] "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):[2] Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E "Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate." Ther Drug Monit 22 (2000):  481-5[3] Spina E, Scordo MG, Avenoso A, Perucca E "Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity." J Clin Psychopharmacol 21 (2001):  108-9[4] "Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2022):[5] "Product Information. Perseris (risperiDONE)." Indivior Inc.  (2022):[6] "Product Information. RisperDAL Consta (risperiDONE)." Janssen Pharmaceuticals  (2021):[7] "Product Information. Teva-Risperidone (risperidone)." Teva Canada Limited  (2022):[8] "Product Information. Perseris (risperidone)." HLS Therapeutics Inc  (2021):[9] "Product Information. Risperdal Consta (risperidone)." Janssen Inc  (2020):[10] "Product Information. Rixadone (riSPERIDONe)." Alphapharm Pty Ltd  (2022):[11] "Product Information. Risperdal Consta (riSPERIDONe)." Janssen-Cilag Pty Ltd  (2020):[12] "Product Information. Risperidone (risperidone)." Krka UK Ltd  (2023):[13] "Product Information. Okedi (risperidone)." ROVI Biotech Ltd  (2022):[14] "Product Information. Risperdal Consta (risperidone)." Janssen-Cilag Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236790, 'Risperidone', 'Rifapentine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone.  Both risperidone and 9-hydroxyrisperidone are substrates of the CYP450 3A4 isoenzyme and P-gp efflux transporter.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.', NULL, 'When risperidone is administered orally, the prescribing information recommends increasing (up to double) the usual dosage gradually (e.g., over 1 to 2 weeks) following the addition of a potent CYP450 3A4/P-gp inducer.  For extended-release injectable formulations of risperidone, patients should be closely monitored for the first 4 to 8 weeks after starting treatment with a potent CYP450 3A4/P-gp inducer.  A dosage increase or supplemental oral risperidone therapy may be required in some cases.  Changes in efficacy and safety should be carefully monitored with any dosage adjustment.  Upon discontinuation of the inducer, risperidone dosage should be reassessed and readjusted accordingly for the anticipated increase in plasma concentrations of risperidone and 9-hydroxyrisperidone.  The prescribing information for individual risperidone products should be consulted for specific recommendations regarding concomitant use with potent CYP450 3A4 inducers.', 'Metabolism', 'Pyrazinamide, Rifamycin, Streptomycin, Cycloserine, Rifabutin, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Prochlorperazine, Asenapine, Thiothixene, Thioridazine, Clozapine, Perphenazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238701/', '[1] "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals  (2001):[2] Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Giacobello T, Madia AG, Perucca E "Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate." Ther Drug Monit 22 (2000):  481-5[3] Spina E, Scordo MG, Avenoso A, Perucca E "Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity." J Clin Psychopharmacol 21 (2001):  108-9[4] "Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2022):[5] "Product Information. Perseris (risperiDONE)." Indivior Inc.  (2022):[6] "Product Information. RisperDAL Consta (risperiDONE)." Janssen Pharmaceuticals  (2021):[7] "Product Information. Teva-Risperidone (risperidone)." Teva Canada Limited  (2022):[8] "Product Information. Perseris (risperidone)." HLS Therapeutics Inc  (2021):[9] "Product Information. Risperdal Consta (risperidone)." Janssen Inc  (2020):[10] "Product Information. Rixadone (riSPERIDONe)." Alphapharm Pty Ltd  (2022):[11] "Product Information. Risperdal Consta (riSPERIDONe)." Janssen-Cilag Pty Ltd  (2020):[12] "Product Information. Risperidone (risperidone)." Krka UK Ltd  (2023):[13] "Product Information. Okedi (risperidone)." ROVI Biotech Ltd  (2022):[14] "Product Information. Risperdal Consta (risperidone)." Janssen-Cilag Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236791, 'Safinamide', 'Risperidone', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238703/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236792, 'Escitalopram', 'Acrivastine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238712/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236793, 'Escitalopram', 'Celecoxib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Valdecoxib, Tamsulosin, Tinidazole, More', 'Phenelzine, Tranylcypromine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238718/', '[1] Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412[2] Claire RJ, Servis ME, Cram DL Jr "Potential interaction between warfarin sodium and fluoxetine." Am J Psychiatry 148 (1991):  1604[3] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949[4] Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8[5] Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9[6] Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990):  213-7[7] "Product Information. Zoloft (sertraline)." Roerig Division  (2001):[8] Woolfrey S, Gammack NS, Dewar MS, Brown PJ "Fluoxetine-warfarin interaction." BMJ 307 (1993):  241[9] "Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):[10] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):[11] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989):  102-6[12] "Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):[13] Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30[14] Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2[15] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):[16] Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132[17] Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6[18] Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8[19] Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4[20] Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5[21] Dent LA, Orrock MW "Warfarin-fluoxetine and diazepam-fluoxetine interaction." Pharmacotherapy 17 (1997):  170-2[22] Ford MA, Anderson ML, Rindone JP, Jaskar DW "Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin." J Clin Psychopharmacol 17 (1997):  110-2[23] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):[24] de Abajo FJ, Rodriguez LA, Montero D "Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study." BMJ 319 (1999):  1106-9[25] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S "Intracranial haemorrhage and use of selective serotonin reuptake inhibitors." Br J Clin Pharmacol 50 (2000):  43-7[26] Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30[27] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42[28] Layton D, Clark DWJ, Pearce GL, Shakir SAW "Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England." Eur J Clin Pharmacol 57 (2001):  167-76[29] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[30] de Maistre E, Allart C, Lecompte T, Bollaert PE "Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors." Am J Med 113 (2002):  530-2[31] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study." Arch Intern Med 163 (2003):  59-64[32] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):[33] Tata LJ, Fortun PJ, Hubbard RB, et al. "Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?" Aliment Pharmacol Ther 22 (2005):  175-81[34] Cerner Multum, Inc. "Australian Product Information." O 0[35] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):[36] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):[37] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC  (2011):[38] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):[39] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236794, 'Escitalopram', 'Chlorcyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine', 'Duloxetine, Vilazodone, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Milnacipran, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238719/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236795, 'Escitalopram', 'Cyclizine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238720/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236796, 'Escitalopram', 'Dimenhydrinate', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Ketotifen, Fexofenadine, Dexchlorpheniramine, Loratadine, Desloratadine, Azelastine', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238724/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236797, 'Escitalopram', 'Levodopa', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone', 'Amantadine, Cabergoline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238732/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236798, 'Escitalopram', 'Melatonin', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine', 'Nitrazepam, Zopiclone, Thiopental', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238738/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236799, 'Escitalopram', 'Methohexital', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Nitrazepam, Zopiclone, Thiopental, Thiopental, Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238739/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236800, 'Escitalopram', 'Pralsetinib', 'Moderate', 'Pralsetinib can cause prolongation of the QT interval.  Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.', NULL, 'Some authorities recommend caution if pralsetinib is coadministered with other agents known to prolong the QT interval.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More', 'Dacomitinib, Pexidartinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238749/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236801, 'Escitalopram', 'Scopolamine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion', 'Nitrazepam, Zopiclone, Thiopental, Homatropine, Atropine, Ephedrine, Methscopolamine, Tropicamide, Phenylephrine, Rolapitant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238750/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236802, 'Escitalopram', 'Turmeric', 'Moderate', 'Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.  Clinical and laboratory observation for hematologic complications is recommended.', 'Synergism', 'Maprotiline, St. John''s Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238757/', '[1] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[2] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002):  391-401[3] Yang X, Thomas DP, Zhang X, et al. "Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation." Arterioscler Thromb Vasc Biol 26 (2006):  85-90[4] New Zealand Medicines and Medical Devices Safety Authority "Medsafe Monitoring Communication: Beware turmeric/curcumin containing products can interact with warfarin.  https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236803, 'Tocilizumab', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238763/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236804, 'Clozapine', 'Tocilizumab', 'Major', 'Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.', NULL, 'Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.', NULL, 'Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.  Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.', 'Synergism', 'Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, More', 'Cyclosporine, Ustekinumab, Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, Apremilast, Inebilizumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238767/', '[1] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Canadian Pharmacists Association "e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink"   (2006):[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236805, 'Tocilizumab', 'Melphalan', 'Moderate', 'The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', NULL, 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.', NULL, 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238785/', '[1] "Product Information. Amevive (alefacept)." Biogen  (2003):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc  (2008):[4] "Product Information. Stelara (ustekinumab)." Centocor Inc  (2009):[5] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals  (2009):[6] "Product Information. Actemra (tocilizumab)." Genentech  (2010):[7] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc.  (2014):[8] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals  (2015):[9] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236806, 'Tocilizumab', 'Melphalan flufenamide', 'Moderate', 'The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', NULL, 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.', NULL, 'Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents.  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly.  Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238786/', '[1] "Product Information. Amevive (alefacept)." Biogen  (2003):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc  (2008):[4] "Product Information. Stelara (ustekinumab)." Centocor Inc  (2009):[5] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals  (2009):[6] "Product Information. Actemra (tocilizumab)." Genentech  (2010):[7] "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc.  (2014):[8] "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals  (2015):[9] "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company  (2016):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236807, 'Tocilizumab', 'Selinexor', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.', NULL, 'Caution is advised during concomitant use of agents with neurotoxic effects.  Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.  Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded.  Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.  If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status.  In some cases, permanent dosage reductions may be required.', 'Synergism', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238822/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp"   (2006):[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236808, 'Yellow Fever Vaccine', 'Tocilizumab', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238836/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236809, 'Varicella Zoster Vaccine (Recombinant)', 'Tocilizumab', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238837/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236810, 'Corticotropin', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238839/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236811, 'Corticotropin', 'Succinylcholine', 'Moderate', 'The neuromuscular blocking effect of succinylcholine may be potentiated by chronic administration of estrogens or high-dose corticosteroids.  Available data suggest that steroids may reduce plasma cholinesterase activity, resulting in decreased metabolic clearance of succinylcholine.', NULL, 'Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered.', NULL, 'Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered.  A lower initial dosage of succinylcholine may be required.', 'Metabolism', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', 'Atracurium, Doxacurium, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Botulinum toxin type A, Cisatracurium', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238897/', '[1] "Product Information. Quelicin Chloride (succinylcholine)." Hospira Inc  (2022):[2] "Product Information. Anectine (succinylcholine)." Sandoz Inc  (2022):[3] "Product Information. Suxamethonium Chloride (suxamethonium)." Advanz Pharma  (2022):[4] "Product Information. Suxamethonium (Accord) (suxamethonium)." Accord Healthcare Pty Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236812, 'Corticotropin', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238907/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236813, 'Corticotropin', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/238908/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236814, 'Interferon gamma-1b', 'Bacillus calmette-guerin substrain tice live antigen', 'Minor', 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.  The mechanism is related to interferon gamma''s immunomodulatory effects.', NULL, 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.', NULL, 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.  The mechanism is related to interferon gamma''s immunomodulatory effects.  The clinical significance is unknown.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239487/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236815, 'Interferon gamma-1b', 'Yellow Fever Vaccine', 'Minor', 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.  The mechanism is related to interferon gamma''s immunomodulatory effects.', NULL, 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.', NULL, 'The concomitant administration of interferon gamma with vaccines may theoretically increase the risk of an exaggerated immune response.  The mechanism is related to interferon gamma''s immunomodulatory effects.  The clinical significance is unknown.', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239541/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236816, 'Ibuprofen', 'Ginkgo biloba', 'Moderate', 'Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Galantamine, Aducanumab', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239550/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J "Spontaneous hyphema associated with ingestion of Ginkgo biloba extract." N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL "Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion." Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ "Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man." Lancet 1 (1987):  248-51[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L "Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy." Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B "A case of cerebral haemorrhage - can Ginkgo biloba be implicated?." Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001):  2163-75[11] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ "Herbal remedies: adverse effects and drug interactions." Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr "Association of Ginko biloba with intracerebral hemorrhage." Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K "Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial." Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE "Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion." Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M "Ginkgo biloba." Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. "Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects." Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L "Herbal medicines and postoperative haemorrhage." Anaesthesia 60 (2005):  725-6[19] Wolf HR "Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?" Drugs R D 7 (2006):  163-72', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236817, 'Ibuprofen', 'Heparin (flush)', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', NULL, 'Caution and monitoring (e.', NULL, 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Protein C, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone', 'Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239551/', '[1] Passannante A, Macik BG "The heparin flush syndrome: a cause of iatrogenic hemorrhage." Am J Med Sci 296 (1988):  71-3[2] "Product Information. Heparin Sodium in Sodium Chloride (heparin flush)." Baxter Healthcare Corporation  (2022):[3] "Product Information. Canusal (heparin flush)." Wockhardt UK Ltd  (2018):[4] "Product Information. Heparinised Saline (Pfizer) (heparinised saline)." Pfizer Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236818, 'Ibuprofen', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Bremelanotide, Cabergoline, Regadenoson, Alprostadil, Ubidecarenone, Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, Misoprostol, Ketoprofen, More', 'Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239565/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236819, 'Ibuprofen', 'Turmeric', 'Moderate', 'Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.  Clinical and laboratory observation for hematologic complications is recommended.', 'Synergism', 'Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239570/', '[1] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[2] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002):  391-401[3] Yang X, Thomas DP, Zhang X, et al. "Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation." Arterioscler Thromb Vasc Biol 26 (2006):  85-90[4] New Zealand Medicines and Medical Devices Safety Authority "Medsafe Monitoring Communication: Beware turmeric/curcumin containing products can interact with warfarin.  https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236820, 'Alteplase', 'Alemtuzumab', 'Moderate', 'Coadministration of alemtuzumab with antiplatelet or anticoagulant drugs may increase the risk of bleeding.  Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia.  The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs.  Patients should be monitored for increased anticoagulant effects and bleeding complications.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Iloprost, Treprostinil, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa, Ascorbic acid, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239572/', '[1] "Product Information. Campath (alemtuzumab)." Berlex Laboratories  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236821, 'Heparin (flush)', 'Alteplase', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', NULL, 'Caution and monitoring (e.', NULL, 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Acenocoumarol, Selexipag, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, Acetylcysteine, Nandrolone', 'Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase, Alteplase, Ascorbic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239578/', '[1] Passannante A, Macik BG "The heparin flush syndrome: a cause of iatrogenic hemorrhage." Am J Med Sci 296 (1988):  71-3[2] "Product Information. Heparin Sodium in Sodium Chloride (heparin flush)." Baxter Healthcare Corporation  (2022):[3] "Product Information. Canusal (heparin flush)." Wockhardt UK Ltd  (2018):[4] "Product Information. Heparinised Saline (Pfizer) (heparinised saline)." Pfizer Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236822, 'Amitriptyline', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239587/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236823, 'Amoxapine', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239588/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236824, 'Anastrozole', 'Medroxyprogesterone acetate', 'Moderate', 'Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer.  Aromatase inhibitors induce a state of estrogen deprivation in postmenopausal women by inhibiting the conversion of androgens to estrogens in adrenal and ovarian tissues, thus estrogen administration would be expected to reverse their therapeutic effects.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', 'Antagonism', 'Darolutamide, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239589/', '[1] "Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):[3] "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236825, 'Anisindione', 'Medroxyprogesterone acetate', 'Moderate', 'Concomitant therapy with estrogen-containing drugs may diminish the therapeutic effects of oral anticoagulants.  Estrogens can increase the plasma levels of certain clotting factors such as fibrinogen, prothrombin, and factors VII and VIII in a dose-dependent manner, resulting in increased risk of thromboembolism, stroke, and/or myocardial infarction.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.  Close clinical and laboratory monitoring are recommended if the combination is prescribed.  Patients should be advised to promptly notify their physician if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.', 'Antagonism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239590/', '[1] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970):  300-6[2] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971):  547-58[3] Schrogie JJ, Solomon HM, Zieve PD "Effect of oral contraceptives on vitamin K-dependent clotting activity." Clin Pharmacol Ther 8 (1967):  670-5[4] Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83[5] Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61[6] Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977):  314-6[7] von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975):  688-92', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236826, 'Betamethasone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239594/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236827, 'Budesonide', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239596/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236828, 'Human C1-esterase inhibitor', 'Medroxyprogesterone acetate', 'Moderate', 'Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.', NULL, 'Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.', NULL, 'Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.  Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.', 'Synergism', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239597/', '[1] "Product Information. Cinryze (C1 esterase inhibitor, human)." ViroPharma Incorporated  (2022):[2] "Product Information. Berinert (C1 esterase inhibitor, human)." CSL Behring LLC  (2022):[3] Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012):  902-9[4] "Product Information. Ruconest (conestat alfa)." Valeant Pharmaceuticals  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236829, 'Calcipotriol (topical)', 'Medroxyprogesterone acetate', 'Moderate', 'Elevations in serum calcium levels have been observed in patients treated with topical vitamin D analogs.  Concomitant use with systemic vitamin D products, calcium supplements, or other agents that can increase serum calcium concentrations such as thiazide diuretics, estrogens, anabolic steroids, and parathyroid hormone or parathyroid hormone analogs may increase the risk of clinically significant hypercalcemia.', NULL, 'Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.', NULL, 'Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.', 'Synergism', 'Tazarotene, Calcipotriol, Trioxsalen, Calcitriol, Methoxsalen', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239598/', '[1] "Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation[2] "Product Information. Vectical (calcitriol topical)." Galderma Laboratories Inc  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236830, 'Calcitriol (topical)', 'Medroxyprogesterone acetate', 'Moderate', 'Elevations in serum calcium levels have been observed in patients treated with topical vitamin D analogs.  Concomitant use with systemic vitamin D products, calcium supplements, or other agents that can increase serum calcium concentrations such as thiazide diuretics, estrogens, anabolic steroids, and parathyroid hormone or parathyroid hormone analogs may increase the risk of clinically significant hypercalcemia.', NULL, 'Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.', NULL, 'Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.', 'Synergism', 'Tazarotene, Calcipotriol, Trioxsalen, Calcitriol, Methoxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcitriol, Calcifediol', 'Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239599/', '[1] "Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation[2] "Product Information. Vectical (calcitriol topical)." Galderma Laboratories Inc  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236831, 'Carfilzomib', 'Medroxyprogesterone acetate', 'Major', 'Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent use of other agents also associated with this adverse effect can potentiate the risk.', NULL, 'Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis.', NULL, 'Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis.  Thromboprophylaxis should be considered according to local treatment protocols.  Close monitoring for thromboembolic events is recommended in patients with known risk factors (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking) for thromboembolism.  Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.', 'Synergism', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Porfimer sodium, More', 'Megestrol acetate, Ulipristal, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239600/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc  (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236832, 'Chenodeoxycholic acid', 'Medroxyprogesterone acetate', 'Moderate', 'Drugs like estrogens, oral contraceptives, fibrates, and possibly other lipid-lowering agents that increase biliary cholesterol secretion may potentiate the risk of cholesterol gallstones and counteract the effectiveness of chenodeoxycholic acid.', NULL, 'Therapeutic effects of chenodeoxycholic acid should be closely monitored if concomitant use with estrogens, oral contraceptives, fibrates, and certain other lipid-lowering agents cannot be avoided.', NULL, 'Therapeutic effects of chenodeoxycholic acid should be closely monitored if concomitant use with estrogens, oral contraceptives, fibrates, and certain other lipid-lowering agents cannot be avoided.', 'Others', 'Maralixibat, Ursodeoxycholic acid, Obeticholic acid, Cholic Acid, Odevixibat', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239601/', '[1] "Product Information. Chenodal (chenodeoxycholic acid)." Manchester Pharmaceutical, Fort Collins, CO.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236833, 'Cimetidine', 'Medroxyprogesterone acetate', 'Minor', 'Theoretically, pharmacologic effects of estrogens may be enhanced during treatment with cimetidine due to increased serum concentrations of endogenous estradiol.  The mechanism is cimetidine inhibition of the 2-hydroxylation of estradiol.', NULL, 'Try to avoid concomitant use of estrogenic agents and H2-receptor antagonists.', NULL, 'Try to avoid concomitant use of estrogenic agents and H2-receptor antagonists.', 'Synergism', 'Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239602/', '[1] Galbraith RA, Michnovicz JJ "The oxidative metabolism of estradiol: inhibition by cimetidine." Trans Assoc Am Physicians 102 (1989):  44-54[2] Galbraith RA, Michnovicz JJ "The effects of cimetidine on the oxidative metabolism of estradiol." N Engl J Med 321 (1989):  269-74[3] Michnovicz JJ, Galbraith RA "Cimetidine inhibits catechol estrogen metabolism in women." Metabolism 40 (1991):  170-4', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236834, 'Clomipramine', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239603/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236835, 'Conestat alfa', 'Medroxyprogesterone acetate', 'Moderate', 'Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.', NULL, 'Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.', NULL, 'Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.  Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.', 'Synergism', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239604/', '[1] "Product Information. Cinryze (C1 esterase inhibitor, human)." ViroPharma Incorporated  (2022):[2] "Product Information. Berinert (C1 esterase inhibitor, human)." CSL Behring LLC  (2022):[3] Gandhi PK, Gentry WM, Bottorff MB "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy 32 (2012):  902-9[4] "Product Information. Ruconest (conestat alfa)." Valeant Pharmaceuticals  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236836, 'Corticotropin', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239606/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236837, 'Tetracosactide', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239608/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236838, 'Dantrolene', 'Medroxyprogesterone acetate', 'Major', 'The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy.', NULL, 'Dantrolene should be used with caution in patients, particularly females over 35 years of age, who are receiving concomitant estrogen therapy.', NULL, 'Dantrolene should be used with caution in patients, particularly females over 35 years of age, who are receiving concomitant estrogen therapy.  Liver function tests (SGOT, SGPT, alkaline phosphatase, total bilirubin) should be performed prior to and during dantrolene therapy at appropriate intervals, and the drug should generally be withheld if significant abnormalities are observed.  Patients treated with dantrolene should be advised to promptly contact their physician if they develop signs and symptoms of hepatocellular injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  The drug should be discontinued if hepatitis is suspected, since early detection and drug withdrawal will increase the likelihood of reversing the damage.  Following resolution of clinical and laboratory abnormalities, reinstitution of dantrolene therapy should be attempted with extreme caution and only if benefit clearly outweighs the risk.', 'Synergism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239609/', '[1] "Product Information. Dantrium (dantrolene)." Procter and Gamble Pharmaceuticals  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236839, 'Deflazacort', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239610/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236840, 'Desipramine', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239611/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236841, 'Dicoumarol', 'Medroxyprogesterone acetate', 'Moderate', 'Concomitant therapy with estrogen-containing drugs may diminish the therapeutic effects of oral anticoagulants.  Estrogens can increase the plasma levels of certain clotting factors such as fibrinogen, prothrombin, and factors VII and VIII in a dose-dependent manner, resulting in increased risk of thromboembolism, stroke, and/or myocardial infarction.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.  Close clinical and laboratory monitoring are recommended if the combination is prescribed.  Patients should be advised to promptly notify their physician if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.', 'Antagonism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239612/', '[1] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970):  300-6[2] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971):  547-58[3] Schrogie JJ, Solomon HM, Zieve PD "Effect of oral contraceptives on vitamin K-dependent clotting activity." Clin Pharmacol Ther 8 (1967):  670-5[4] Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83[5] Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61[6] Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977):  314-6[7] von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975):  688-92', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236842, 'Doxepin', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239613/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236843, 'Eslicarbazepine', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.', 'Metabolism', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More', 'Estetrol, Diethylstilbestrol, Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239614/', '[1] Crawford P, Chadwick DJ, Martin C, et al. "The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids." Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992):  711-6[4] Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD "Oral contraceptives and griseofulvin interaction." Drug Intell Clin Pharm 20 (1986):  384[6] Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH "Rifampin, oral contraceptives, and pregnancy." JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP "Letter: Drugs affecting oral contraceptives." Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. "The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy." Contraception 22 (1980):  495-503[13] Dossetor J "Drug interactions with oral contraceptives." Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH "Rifampin drug interactions." Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L "Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives." JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H "Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man." Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. "The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women." Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD "Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF "Do anticonvulsants reduce the efficacy of oral contraceptives?" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA "Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database." Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F "Use of oral contraceptives by women with epilepsy." JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 2 (1974):  600[24] Janz D, Schmidt D "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974):  1113[25] Curran MA "Drug interactions with the pill." Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML "Pharmacokinetic drug interactions with oral contraceptives." Clin Pharmacokinet 18 (1990):  472-84[27] D''Arcy PF "Drug interactions with oral contraceptives." Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M "Interaction between estrogen and dilantin in a menopausal woman." N Engl J Med 304 (1981):  788-9[29] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997):  2453-8[31] Michalets EL "Update: clinically significant cytochrome P-450 drug interactions." Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK "Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone." J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. "The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive." Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP "Possible interaction between oxcarbazepine and an oral contraceptive." Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K "St John''s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review." Contraception 59 (1999):  71-8[40] Zachariassen RD "Loss of oral contraceptive efficacy by concurrent antibiotic administration." Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML "Drug interactions between oral contraceptives and antibiotics." Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] "Unwanted pregnancy on self-medication with St John''s wort despite hormonal contraception." Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J "Interaction of St John''s wort with low-dose oral contraceptive therapy: a randomized controlled trial." Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. "The interaction between St John''s wort and an oral contraceptive." Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD "The effect of St. John''s wort on the efficacy of oral contraception." Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W "Failure of oral contraceptives because of St. John''s wort." Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf"   (2016):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236844, 'Exemestane', 'Medroxyprogesterone acetate', 'Moderate', 'Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer.  Aromatase inhibitors induce a state of estrogen deprivation in postmenopausal women by inhibiting the conversion of androgens to estrogens in adrenal and ovarian tissues, thus estrogen administration would be expected to reverse their therapeutic effects.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', 'Antagonism', 'Darolutamide, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239616/', '[1] "Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):[3] "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236845, 'Fludrocortisone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239618/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236846, 'Hemin', 'Medroxyprogesterone acetate', 'Major', 'Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin.  In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.', NULL, 'Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.', NULL, 'Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.', 'Antagonism', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239620/', '[1] "Product Information. Panhematin (hemin)." Recordati Rare Diseases Inc  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236847, 'Hyaluronidase', 'Medroxyprogesterone acetate', 'Minor', 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.', NULL, 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.', NULL, 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.', 'Antagonism', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239621/', '[1] "Product Information. Vitrase (hyaluronidase)." Bausch and Lomb Americas, Inc.  (2004):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236848, 'Hydrocortisone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac, Tetracycline, Acetylsalicylic acid, Minocycline, Amphotericin B, Doxycycline, Metronidazole, Epinephrine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239622/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236849, 'Imipramine', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239623/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236850, 'Medroxyprogesterone acetate', 'Lenalidomide', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.  It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events.  The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors.  If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated.  Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.  Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Norelgestromin, Norethisterone, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Megestrol acetate, Progesterone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239625/', '[1] "Product Information. Revlimid (lenalidomide)." Celgene Corporation  (2006):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236851, 'Medroxyprogesterone acetate', 'Letrozole', 'Moderate', 'Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer.  Aromatase inhibitors induce a state of estrogen deprivation in postmenopausal women by inhibiting the conversion of androgens to estrogens in adrenal and ovarian tissues, thus estrogen administration would be expected to reverse their therapeutic effects.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', 'Antagonism', 'Darolutamide, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239626/', '[1] "Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):[3] "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236852, 'Medroxyprogesterone acetate', 'Levothyroxine', 'Moderate', 'Estrogens may increase serum thyrotropin concentration, which could be harmful in patients with thyroid cancer receiving thyroxine for thyrotropin suppression or increase dosage requirements in patients with hypothyroidism receiving thyroxine for replacement therapy.  Estrogens are known to increase serum thyroid-binding globulin concentration in a dose-dependent manner.  Consequently, there may be a reduction in unbound, or free, thyroxine available for hormone activity, which, in turn, leads to an increase in serum thyrotropin concentration.  Normally, thyroxine secretion can increase to compensate for this effect, but patients with hypothyroidism lack the mechanism to adapt.  Limited evidence suggests that transdermal estrogen therapy may not affect thyroid-binding globulin concentrations; however, more data are required to confirm that.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.  Patients should be advised to contact their physician if clinical manifestations of hypothyroidism occur, such as fatigue, cold intolerance, constipation, unexplained weight gain, depression, joint or muscle pain, thinning hair or hair loss, dry skin, hoarseness, and abnormal menstrual periods.', 'Distribution', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, Megestrol acetate, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239628/', '[1] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical  (2002):[2] Chetkowski RJ, Meldrum DR, Steingold KA, et al. "Biologic effects of transdermal estradiol." N Engl J Med 314 (1986):  1615-20[3] Arafah BM "Increased need for thyroxine in women with hypothyroidism during estrogen therapy." N Engl J Med 344 (2001):  1743-9[4] Utiger RD "Estrogen, thyroxine binding in serum, and thyroxine therapy." N Engl J Med 344 (2001):  1784-5[5] Irving S, Vadiveloo T, Leese GP "Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)." Clin Endocrinol (Oxf)  (2014):[6] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236853, 'Medroxyprogesterone acetate', 'Liothyronine', 'Moderate', 'Estrogens may increase serum thyrotropin concentration, which could be harmful in patients with thyroid cancer receiving thyroxine for thyrotropin suppression or increase dosage requirements in patients with hypothyroidism receiving thyroxine for replacement therapy.  Estrogens are known to increase serum thyroid-binding globulin concentration in a dose-dependent manner.  Consequently, there may be a reduction in unbound, or free, thyroxine available for hormone activity, which, in turn, leads to an increase in serum thyrotropin concentration.  Normally, thyroxine secretion can increase to compensate for this effect, but patients with hypothyroidism lack the mechanism to adapt.  Limited evidence suggests that transdermal estrogen therapy may not affect thyroid-binding globulin concentrations; however, more data are required to confirm that.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.  Patients should be advised to contact their physician if clinical manifestations of hypothyroidism occur, such as fatigue, cold intolerance, constipation, unexplained weight gain, depression, joint or muscle pain, thinning hair or hair loss, dry skin, hoarseness, and abnormal menstrual periods.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239629/', '[1] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical  (2002):[2] Chetkowski RJ, Meldrum DR, Steingold KA, et al. "Biologic effects of transdermal estradiol." N Engl J Med 314 (1986):  1615-20[3] Arafah BM "Increased need for thyroxine in women with hypothyroidism during estrogen therapy." N Engl J Med 344 (2001):  1743-9[4] Utiger RD "Estrogen, thyroxine binding in serum, and thyroxine therapy." N Engl J Med 344 (2001):  1784-5[5] Irving S, Vadiveloo T, Leese GP "Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)." Clin Endocrinol (Oxf)  (2014):[6] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236854, 'Medroxyprogesterone acetate', 'Liotrix', 'Moderate', 'Estrogens may increase serum thyrotropin concentration, which could be harmful in patients with thyroid cancer receiving thyroxine for thyrotropin suppression or increase dosage requirements in patients with hypothyroidism receiving thyroxine for replacement therapy.  Estrogens are known to increase serum thyroid-binding globulin concentration in a dose-dependent manner.  Consequently, there may be a reduction in unbound, or free, thyroxine available for hormone activity, which, in turn, leads to an increase in serum thyrotropin concentration.  Normally, thyroxine secretion can increase to compensate for this effect, but patients with hypothyroidism lack the mechanism to adapt.  Limited evidence suggests that transdermal estrogen therapy may not affect thyroid-binding globulin concentrations; however, more data are required to confirm that.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.  Patients should be advised to contact their physician if clinical manifestations of hypothyroidism occur, such as fatigue, cold intolerance, constipation, unexplained weight gain, depression, joint or muscle pain, thinning hair or hair loss, dry skin, hoarseness, and abnormal menstrual periods.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239630/', '[1] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical  (2002):[2] Chetkowski RJ, Meldrum DR, Steingold KA, et al. "Biologic effects of transdermal estradiol." N Engl J Med 314 (1986):  1615-20[3] Arafah BM "Increased need for thyroxine in women with hypothyroidism during estrogen therapy." N Engl J Med 344 (2001):  1743-9[4] Utiger RD "Estrogen, thyroxine binding in serum, and thyroxine therapy." N Engl J Med 344 (2001):  1784-5[5] Irving S, Vadiveloo T, Leese GP "Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)." Clin Endocrinol (Oxf)  (2014):[6] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236855, 'Melatonin', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 may substantially increase the plasma concentrations of melatonin.  Data from available studies suggest that melatonin is primarily metabolized by CYP450 1A2, with possible contribution from CYP450 2C19 and 2C9.  Coadministration of fluvoxamine, a potent CYP450 1A2 inhibitor that also inhibits CYP450 2C19 and 2C9, increased melatonin systemic exposure (AUC) by 17-fold and maximum plasma concentration (Cmax) by 12-fold.  Contraceptives containing ethinyl estradiol, which can inhibit CYP450 1A2, may lead to a 4- to 5-fold increase in melatonin concentration.', NULL, 'Caution is advised when melatonin is used concomitantly with CYP450 1A2 inhibitors.', NULL, 'Caution is advised when melatonin is used concomitantly with CYP450 1A2 inhibitors.  Patients should be monitored closely for adverse effects such as excessive drowsiness, headache, lethargy, dizziness, irritability, nervousness, restlessness, anxiety, abdominal pain, and dyspepsia.', 'Metabolism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239633/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236856, 'Methylprednisolone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Minocycline, Clindamycin, Vitamin A, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239634/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236857, 'Metyrapone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogen therapy may reduce the response to metyrapone test.  The mechanism is related to an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in decreased cortisol clearance.  The increase in circulating cortisol may directly interfere with test results, since the pharmacologic effect of metyrapone is to inhibit adrenal production of cortisol and corticosterone in order to elicit an increase in ACTH production by the pituitary.', NULL, 'Clinicians should recognize the potential for a diminished response to metyrapone test in patients treated with estrogens.', NULL, 'Clinicians should recognize the potential for a diminished response to metyrapone test in patients treated with estrogens.', 'Antagonism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Edrophonium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239635/', '[1] "Product Information. femhrt (ethinyl estradiol-norethindrone)." Parke-Davis[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236858, 'Morphine', 'Medroxyprogesterone acetate', 'Minor', 'Oral contraceptives induce glucuronidation and may decrease plasma concentrations of morphine, diamorphine, and other opioids.', NULL, 'Oral contraceptives may influence opioid analgesic effects and opioid dosage may need to be adjusted.', NULL, 'Oral contraceptives may influence opioid analgesic effects and opioid dosage may need to be adjusted.', 'Metabolism', 'Megestrol acetate, Estetrol, Megestrol acetate, Megestrol acetate, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Triptorelin', 'Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239639/', '[1] Shenfield GM, Griffin JM "Clinical pharmacokinetics of contraceptive steroids: an update." Clin Pharmacokinet 20 (1991):  15-37[2] "Product Information. NuvaRing (ethinyl estradiol-etonogestrel)." Organon  (2001):[3] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[4] "Product Information. VyLibra (ethinyl estradiol-norgestimate)." Afaxys Inc.  (2022):[5] Ribeiro-Dasilva MC, Shinal RM, Glover T, Williams RS, Staud R, Riley JL 3rd, Fillingim RB "Evaluation of menstrual cycle effects on morphine and pentazocine analgesia" Pain 152 (2011):  614-622', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236859, 'Nafcillin', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.', 'Metabolism', 'Estetrol, Diethylstilbestrol, Histrelin, Leuprolide, Bicalutamide, Triptorelin, Goserelin', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239640/', '[1] Crawford P, Chadwick DJ, Martin C, et al. "The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids." Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992):  711-6[4] Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD "Oral contraceptives and griseofulvin interaction." Drug Intell Clin Pharm 20 (1986):  384[6] Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH "Rifampin, oral contraceptives, and pregnancy." JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP "Letter: Drugs affecting oral contraceptives." Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. "The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy." Contraception 22 (1980):  495-503[13] Dossetor J "Drug interactions with oral contraceptives." Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH "Rifampin drug interactions." Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L "Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives." JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H "Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man." Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. "The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women." Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD "Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF "Do anticonvulsants reduce the efficacy of oral contraceptives?" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA "Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database." Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F "Use of oral contraceptives by women with epilepsy." JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 2 (1974):  600[24] Janz D, Schmidt D "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974):  1113[25] Curran MA "Drug interactions with the pill." Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML "Pharmacokinetic drug interactions with oral contraceptives." Clin Pharmacokinet 18 (1990):  472-84[27] D''Arcy PF "Drug interactions with oral contraceptives." Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M "Interaction between estrogen and dilantin in a menopausal woman." N Engl J Med 304 (1981):  788-9[29] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997):  2453-8[31] Michalets EL "Update: clinically significant cytochrome P-450 drug interactions." Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK "Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone." J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. "The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive." Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP "Possible interaction between oxcarbazepine and an oral contraceptive." Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K "St John''s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review." Contraception 59 (1999):  71-8[40] Zachariassen RD "Loss of oral contraceptive efficacy by concurrent antibiotic administration." Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML "Drug interactions between oral contraceptives and antibiotics." Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] "Unwanted pregnancy on self-medication with St John''s wort despite hormonal contraception." Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J "Interaction of St John''s wort with low-dose oral contraceptive therapy: a randomized controlled trial." Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. "The interaction between St John''s wort and an oral contraceptive." Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD "The effect of St. John''s wort on the efficacy of oral contraception." Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W "Failure of oral contraceptives because of St. John''s wort." Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf"   (2016):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236860, 'Nortriptyline', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239641/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236861, 'Osilodrostat', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Dienogest, Estetrol, Etynodiol, Dienogest, Etynodiol, Dienogest, Etynodiol, Diethylstilbestrol', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239643/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc  (2020):[2] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Australia Pty Ltd  (2022):[3] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases UK Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236862, 'Ospemifene', 'Medroxyprogesterone acetate', 'Moderate', 'The concurrent use of ospemifene with estrogens or other estrogen agonists/antagonists has not been evaluated.', NULL, 'Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.', NULL, 'Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.', 'Others', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Prasterone, Danazol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239644/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Osphena (ospemifene)." Shionogi USA Inc  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236863, 'Pomalidomide', 'Medroxyprogesterone acetate', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.  Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.', 'Synergism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239647/', '[1] "Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc  (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236864, 'Prednisolone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluorometholone, Indomethacin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239648/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236865, 'Prednisone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239649/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236866, 'Protriptyline', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239650/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236867, 'Raloxifene', 'Medroxyprogesterone acetate', 'Moderate', 'The concurrent use of raloxifene and systemic estrogen or hormone replacement therapy has not been evaluated in prospective clinical trials.', NULL, 'Due to the lack of clinical data, use of raloxifene with systemic estrogens is not recommended.', NULL, 'Due to the lack of clinical data, use of raloxifene with systemic estrogens is not recommended.', 'Others', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, Etonogestrel, More', 'Prasterone, Danazol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239651/', '[1] "Product Information. Evista (raloxifene)." Lilly, Eli and Company  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236868, 'Ropinirole', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with estrogen-containing drugs may increase the plasma concentrations of ropinirole.The mechanism of interaction has not been described.', NULL, 'Dosage adjustment for ropinirole should not be necessary in patients already on estrogen therapy because patients must be carefully titrated to tolerance or adequate effect.', NULL, 'Dosage adjustment for ropinirole should not be necessary in patients already on estrogen therapy because patients must be carefully titrated to tolerance or adequate effect.  However, if estrogen therapy is initiated or discontinued during treatment with ropinirole, then patients should be monitored for altered ropinirole effects and the dosage adjusted as necessary.  Patients should be advised to notify their physician if they experience agitation, orthostasis, sedation, confusion, hallucinations, and/or increased dyskinesia, flushing, dry mouth, sweating, or heart rate.', 'Others', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239652/', '[1] "Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236869, 'Saw palmetto', 'Medroxyprogesterone acetate', 'Minor', 'Theoretically, coadministration with saw palmetto may interfere with the pharmacologic effects of estrogen-containing drugs including oral contraceptives.  Saw palmetto has been observed in one study to possess antiestrogenic effects.  However, the interaction has not been reported.', NULL, 'Try to avoid taking saw palmetto and estrogenic medications at the same time to avoid unexpected medical events.', NULL, 'Try to avoid taking saw palmetto and estrogenic medications at the same time to avoid unexpected medical events.', 'Antagonism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239653/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236870, 'Selumetinib', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.', NULL, 'Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.', NULL, 'Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.', 'Antagonism', 'Megestrol acetate, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Estradiol, Diethylstilbestrol, Histrelin, Megestrol acetate, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239654/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236871, 'Succinylcholine', 'Medroxyprogesterone acetate', 'Moderate', 'The neuromuscular blocking effect of succinylcholine may be potentiated by chronic administration of estrogens or high-dose corticosteroids.  Available data suggest that steroids may reduce plasma cholinesterase activity, resulting in decreased metabolic clearance of succinylcholine.', NULL, 'Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered.', NULL, 'Patients receiving chronic therapy with estrogens or corticosteroids should be monitored for increased or prolonged neuromuscular blockade when succinylcholine is administered.  A lower initial dosage of succinylcholine may be required.', 'Metabolism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Atracurium, Doxacurium, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Botulinum toxin type A, Cisatracurium', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239656/', '[1] "Product Information. Quelicin Chloride (succinylcholine)." Hospira Inc  (2022):[2] "Product Information. Anectine (succinylcholine)." Sandoz Inc  (2022):[3] "Product Information. Suxamethonium Chloride (suxamethonium)." Advanz Pharma  (2022):[4] "Product Information. Suxamethonium (Accord) (suxamethonium)." Accord Healthcare Pty Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236872, 'Testolactone', 'Medroxyprogesterone acetate', 'Moderate', 'Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer.  Aromatase inhibitors induce a state of estrogen deprivation in postmenopausal women by inhibiting the conversion of androgens to estrogens in adrenal and ovarian tissues, thus estrogen administration would be expected to reverse their therapeutic effects.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', NULL, 'Use of estrogen-containing products should be avoided during aromatase inhibitor therapy.', 'Antagonism', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239658/', '[1] "Product Information. Femara (letrozole)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Arimidex (anastrozole)." Astra-Zeneca Pharmaceuticals  (2001):[3] "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236873, 'Thalidomide', 'Medroxyprogesterone acetate', 'Major', 'Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, oestrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of thalidomide.  When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism.  This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.', NULL, 'Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.  Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors.  If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy initiated.  Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.  Anticoagulation therapy should be continued during the remaining course of thalidomide treatment.', 'Synergism', 'Ulipristal, Norethisterone, Norelgestromin, Norgestimate, Etynodiol, Levonorgestrel, Desogestrel, Estetrol, Etonogestrel, Norgestrel, Progesterone, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239659/', '[1] "Product Information. Thalomid (thalidomide)." Celgene Corporation  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236874, 'Thyroid, porcine', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may increase serum thyrotropin concentration, which could be harmful in patients with thyroid cancer receiving thyroxine for thyrotropin suppression or increase dosage requirements in patients with hypothyroidism receiving thyroxine for replacement therapy.  Estrogens are known to increase serum thyroid-binding globulin concentration in a dose-dependent manner.  Consequently, there may be a reduction in unbound, or free, thyroxine available for hormone activity, which, in turn, leads to an increase in serum thyrotropin concentration.  Normally, thyroxine secretion can increase to compensate for this effect, but patients with hypothyroidism lack the mechanism to adapt.  Limited evidence suggests that transdermal estrogen therapy may not affect thyroid-binding globulin concentrations; however, more data are required to confirm that.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.', NULL, 'In patients treated with thyroxine, serum thyrotropin should be measured approximately 12 weeks after estrogen therapy is initiated, changed or discontinued, and the thyroxine dosage adjusted accordingly.  Patients should be advised to contact their physician if clinical manifestations of hypothyroidism occur, such as fatigue, cold intolerance, constipation, unexplained weight gain, depression, joint or muscle pain, thinning hair or hair loss, dry skin, hoarseness, and abnormal menstrual periods.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239660/', '[1] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical  (2002):[2] Chetkowski RJ, Meldrum DR, Steingold KA, et al. "Biologic effects of transdermal estradiol." N Engl J Med 314 (1986):  1615-20[3] Arafah BM "Increased need for thyroxine in women with hypothyroidism during estrogen therapy." N Engl J Med 344 (2001):  1743-9[4] Utiger RD "Estrogen, thyroxine binding in serum, and thyroxine therapy." N Engl J Med 344 (2001):  1784-5[5] Irving S, Vadiveloo T, Leese GP "Drugs that interact with levothyroxine; an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)." Clin Endocrinol (Oxf)  (2014):[6] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236875, 'Tipranavir', 'Medroxyprogesterone acetate', 'Moderate', 'Use of tipranavir in combination with estrogens may be associated with an increased risk of skin rash.', NULL, 'Women who use estrogens should be advised of a potentially increased risk of skin rash during concomitant treatment with tipranavir.', NULL, 'Women who use estrogens should be advised of a potentially increased risk of skin rash during concomitant treatment with tipranavir.  If a rash occurs, it is usually mild to moderate.  Nevertheless, patients should be instructed to contact their physician promptly, as a temporary discontinuation of tipranavir or the estrogen may be necessary.', 'Synergism', 'Norelgestromin, Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, Norgestrel, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239661/', '[1] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236876, 'Topiramate', 'Medroxyprogesterone acetate', 'Major', 'Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is topiramate induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of steroidal hormones.', NULL, 'The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.', NULL, 'The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.  Some clinicians and manufacturers recommend that patients on topiramate dosages at or above 200 mg/day who are taking oral contraceptives should receive a preparation containing no less than 30 or 35 mcg of estrogen, while others recommend at least 50 mcg.  Intrauterine systems are unlikely to be significantly affected because of their local action, thus they may be preferable to other routes of administration.  Patients should be advised to report any change in their bleeding patterns, although contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.  Because use of topiramate can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Counseling should be provided regarding the use of alternative (non-hormonal) or additional (back-up) pregnancy prevention methods during and for at least 28 days after discontinuing topiramate.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Alternative, nonenzyme-inducing anticonvulsants that are not believed to interact significantly with hormonal contraceptives include clonazepam, ethosuximide, gabapentin, levetiracetam, pregabalin, tiagabine, valproic acid, vigabatrin, and zonisamide.', 'Metabolism', 'Megestrol acetate, Estetrol, Megestrol acetate, Megestrol acetate, Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Goserelin', 'Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239663/', '[1] "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):[2] "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical  (2001):[3] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000):  355-65[4] Rosenfeld WE, Doose DR, Walker SA, Nayak RK "Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy." Epilepsia 38 (1997):  317-23[5] Patsalos PN, Froscher W, Pisani F, van Rijn CM "The importance of drug interactions in epilepsy therapy." Epilepsia 43 (2002):  365-85[6] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M "Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects." Epilepsia 44 (2003):  540-9[7] Nallani SC, Glauser TA, Hariparsad N, et al. "Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate." Epilepsia 44 (2003):  1521-8[8] Bialer M, Doose DR, Murthy B, et al. "Pharmacokinetic interactions of topiramate." Clin Pharmacokinet 43 (2004):  763-80[9] "FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception." J Fam Plann Reprod Health Care 31 (2005):  139-51[10] Perucca E "Clinically relevant drug interactions with antiepileptic drugs." Br J Clin Pharmacol 61 (2006):  246-255[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] Harden CL, Leppik I "Optimizing therapy of seizures in women who use oral contraceptives." Neurology 67(12 Suppl 4) (2006):  S56-8[13] Cerner Multum, Inc. "Australian Product Information." O 0[14] "Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):[15] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[16] "Product Information. Nexplanon (etonogestrel)." Organon Pharmaceuticals  (2017):[17] Sunaga T, Cicali B, Schmidt S, Brown J "Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system." Contraception 103(Issue 4) (2021):  222-4[18] Doodipala SR "Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives." Expert Rev Clin Pharmacol 3 (2010):  183-92', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236877, 'Triamcinolone', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239664/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236878, 'Triamcinolone (ophthalmic)', 'Medroxyprogesterone acetate', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids.  The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.  Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Distribution', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, More', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239665/', '[1] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984):  505-11[2] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984):  655-64[3] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986):  425-9[4] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986):  301-8[5] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983):  702-8[6] "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical[7] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):[8] "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236879, 'Trimipramine', 'Medroxyprogesterone acetate', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.', NULL, 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy.  Simultaneous TCA toxicity and reduced effects have been reported.  Akathisia has also been reported in some women taking this combination.  The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.  The clinical significance of this interaction has not been established.  Monitoring for altered effects may be advisable during concomitant therapy.  Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Ulipristal, Norethisterone, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Estetrol, More', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239666/', '[1] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984):  792-7[2] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987):  177-87[3] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972):  143-4[4] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972):  702-3[5] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973):  560[6] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984):  696-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236880, 'Tucatinib', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates.  The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes.', NULL, 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.', NULL, 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.', 'Metabolism', 'Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel, Megestrol acetate, Progesterone, Etynodiol, Megestrol acetate, Etynodiol, Levonorgestrel, More', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239667/', '[1] "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236881, 'Voxelotor', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with voxelotor may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by voxelotor.  The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', NULL, 'Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.', NULL, 'Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voxelotor is added to or withdrawn from therapy.', 'Metabolism', 'Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel, Megestrol acetate, Progesterone, Etynodiol, Megestrol acetate, Etynodiol, Levonorgestrel, More', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239669/', '[1] "Product Information. Oxbryta (voxelotor)." Global Blood Therapeutics, Inc.  (2019):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236882, 'Warfarin', 'Medroxyprogesterone acetate', 'Moderate', 'Concomitant therapy with estrogen-containing drugs may diminish the therapeutic effects of oral anticoagulants.  Estrogens can increase the plasma levels of certain clotting factors such as fibrinogen, prothrombin, and factors VII and VIII in a dose-dependent manner, resulting in increased risk of thromboembolism, stroke, and/or myocardial infarction.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.  Close clinical and laboratory monitoring are recommended if the combination is prescribed.  Patients should be advised to promptly notify their physician if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.', 'Antagonism', 'Ulipristal, Norelgestromin, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Desogestrel, Dienogest, Etonogestrel, Norgestrel, Megestrol acetate, More', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239670/', '[1] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970):  300-6[2] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971):  547-58[3] Schrogie JJ, Solomon HM, Zieve PD "Effect of oral contraceptives on vitamin K-dependent clotting activity." Clin Pharmacol Ther 8 (1967):  670-5[4] Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985):  73-83[5] Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982):  758-61[6] Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977):  314-6[7] von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975):  688-92', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236883, 'Daclatasvir', 'Pioglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Telaprevir, Rilpivirine, Dolutegravir, Cobicistat, Brincidofovir, Famciclovir, Doravirine, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239693/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236884, 'Fluocinolone acetonide', 'Pioglitazone', 'Minor', 'The efficacy of insulin and other antidiabetic agents may be diminished by topical corticosteroids, particularly during prolonged or indiscriminate use.  Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.', NULL, 'Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Close clinical monitoring of glycemic control is recommended if topical corticosteroids are administered chronically and/or to large areas in diabetic patients.', 'Antagonism', 'Fluorometholone, Hydrocortisone butyrate, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Flurbiprofen, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239695/', '[1] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42[2] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993):  84-7[3] Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522[4] Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim[5] "Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):[6] "Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):[7] "Product Information. Temovate (clobetasol topical)." Glaxo Wellcome[8] "Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236885, 'Pralsetinib', 'Pioglitazone', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Canagliflozin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239707/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236886, 'Simeprevir', 'Pioglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Guar gum', 'Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Tioconazole, Furazolidone, Diiodohydroxyquinoline, Oxytetracycline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239708/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236887, 'Sofosbuvir', 'Pioglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Simvastatin, Guar gum, Rosuvastatin', 'Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Telaprevir, Rilpivirine, Dolutegravir, Cobicistat, Brincidofovir, Famciclovir, Doravirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239710/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences  (2013):[4] "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences  (2014):[5] "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC  (2022):[6] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):[7] Cerner Multum, Inc "Malaysia product information." O 0 (2015):[8] "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc  (2016):[9] "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences  (2016):[10] "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences  (2017):[11] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical  (2017):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236888, 'Adefovir dipivoxil', 'Ketorolac', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Homatropine, Atropine, Scopolamine, Methscopolamine, Ephedrine, Tropicamide, Phenylephrine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239715/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236889, 'Alemtuzumab', 'Ketorolac', 'Moderate', 'Coadministration of alemtuzumab with drugs that have antiplatelet or anticoagulant effects, such as nonsteroidal anti-inflammatory drugs (NSAIDs), may increase the risk of bleeding.  Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia.  The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with NSAIDS.', NULL, 'Caution is recommended if alemtuzumab is used concomitantly with NSAIDS.  Patients should be monitored for increased anticoagulant effects and bleeding complications.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.', 'Synergism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Homatropine, Atropine, Scopolamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239716/', '[1] "Product Information. Campath (alemtuzumab)." Berlex Laboratories  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236890, 'Ginkgo biloba', 'Ketorolac', 'Moderate', 'Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and thrombolytic agents.  Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.', NULL, 'Patients should consult a healthcare provider before taking any herbal or alternative medicine.  In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery.  In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet, NSAID or thrombolytic therapy, the potential for an interaction should be considered.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Rivastigmine, Galantamine, Aducanumab, Memantine, Tacrine', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239724/', '[1] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[2] Rosenblatt M, Mindel J "Spontaneous hyphema associated with ingestion of Ginkgo biloba extract." N Engl J Med 336 (1997):  1108[3] Rowin J, Lewis SL "Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion." Neurology 46 (1996):  1775-6[4] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ "Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man." Lancet 1 (1987):  248-51[5] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000):  134-8[6] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[7] Vaes LP, Chyka PA "Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence." Ann Pharmacother 34 (2000):  1478-82[8] Fessenden JM, Wittenborn W, Clarke L "Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy." Am Surg 67 (2001):  33-5[9] Benjamin J, Muir T, Briggs K, Pentland B "A case of cerebral haemorrhage - can Ginkgo biloba be implicated?." Postgrad Med J 77 (2001):  112-3[10] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001):  2163-75[11] Evans V "Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use." J Neurosci Nurs 32 (2000):  229-32[12] Cupp MJ "Herbal remedies: adverse effects and drug interactions." Am Fam Physician 59 (1999):  1239-45[13] Matthews MK Jr "Association of Ginko biloba with intracerebral hemorrhage." Neurology 50 (1998):  1933-4[14] Engelsen J, Nielsen JD, Winther K "Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial." Thromb Haemost 87 (2002):  1075-6[15] Fong KC, Kinnear PE "Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion." Postgrad Med J 79 (2003):  531-2[16] Sierpina VS, Wollschlaeger B, Blumenthal M "Ginkgo biloba." Am Fam Physician 68 (2003):  923-6[17] Jiang X, Williams KM, Liauw WS, et al. "Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects." Br J Clin Pharmacol 59 (2005):  425-32[18] Jayasekera N, Moghal A, Kashif F, Karalliedde L "Herbal medicines and postoperative haemorrhage." Anaesthesia 60 (2005):  725-6[19] Wolf HR "Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?" Drugs R D 7 (2006):  163-72', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236891, 'Heparin (flush)', 'Ketorolac', 'Moderate', 'Concomitant use of heparin flush and drugs that interfere with platelet function or coagulation or drugs that commonly cause thrombocytopenia may potentiate the risk of bleeding complications.  Although uncommon, inadvertent anticoagulation resulting in hemorrhagic events may occur with heparin flushes, particularly during repeated or excessive use or administration of higher concentration flush solutions.', NULL, 'Caution and monitoring (e.', NULL, 'Caution and monitoring (e.g., platelet counts, hematocrits, tests for occult blood in stools) are advised when heparin flushes are given to patients receiving systemic anticoagulants, platelet inhibitors, antithrombotic agents, thrombolytics, or drugs with known risks of thrombocytopenia or bleeding.  An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.', 'Synergism', 'Protein C, Acenocoumarol, Selexipag, Pentosan polysulfate, Vitamin A, Ascorbic acid, Nandrolone', 'Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Ephedrine, Tropicamide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239725/', '[1] Passannante A, Macik BG "The heparin flush syndrome: a cause of iatrogenic hemorrhage." Am J Med Sci 296 (1988):  71-3[2] "Product Information. Heparin Sodium in Sodium Chloride (heparin flush)." Baxter Healthcare Corporation  (2022):[3] "Product Information. Canusal (heparin flush)." Wockhardt UK Ltd  (2018):[4] "Product Information. Heparinised Saline (Pfizer) (heparinised saline)." Pfizer Australia Pty Ltd  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236892, 'Turmeric', 'Ketorolac', 'Moderate', 'Turmeric may potentiate the bleeding risk associated with drugs that interfere with platelet function or coagulation.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.', NULL, 'Caution is advised when turmeric-containing products are used concomitantly with drugs that affect hemostasis such as anticoagulants, antiplatelet agents, nonsteroidal anti-inflammatory drugs, serotonin reuptake inhibitors, and thrombolytic agents.  Clinical and laboratory observation for hematologic complications is recommended.', 'Synergism', 'Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Homatropine, Atropine, Scopolamine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239743/', '[1] Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000):  1221-7; quiz 1228-30[2] Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002):  391-401[3] Yang X, Thomas DP, Zhang X, et al. "Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation." Arterioscler Thromb Vasc Biol 26 (2006):  85-90[4] New Zealand Medicines and Medical Devices Safety Authority "Medsafe Monitoring Communication: Beware turmeric/curcumin containing products can interact with warfarin.  https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236893, 'Capreomycin', 'Acyclovir', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239745/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236894, 'Colistimethate', 'Acyclovir', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239746/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236895, 'Acyclovir', 'Polymyxin B', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Rifamycin, Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239751/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236896, 'Acyclovir', 'Telavancin', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', NULL, 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tinidazole, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239752/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236897, 'Dapsone (topical)', 'Benzoyl peroxide (topical)', 'Minor', 'In one clinical study, topical application of dapsone followed by benzoyl peroxide in subjects with acne vulgaris was associated with a temporary local yellow or orange discoloration of the skin and facial hair in 7 out of 95 subjects, with resolution in 4 to 57 days.  The mechanism of interaction is unknown.', NULL, 'Based on current data, skin color changes caused by the combination of the two are transient and reversible, so no dosing adjustments are necessary.', NULL, 'Based on current data, skin color changes caused by the combination of the two are transient and reversible, so no dosing adjustments are necessary.', 'Others', 'Minocycline, Clindamycin, Vitamin A, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239757/', '[1] "Product Information. Aczone (dapsone topical)." QLT USA, Inc  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236898, 'Dapsone (topical)', 'Bupivacaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Meloxicam', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Clofazimine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239758/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236899, 'Dapsone (topical)', 'Bupivacaine (liposome)', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Meloxicam', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239759/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236900, 'Dapsone (topical)', 'Chloroprocaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Meloxicam', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239760/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236901, 'Dapsone', 'Dapsone (topical)', 'Moderate', 'Coadministration of oral or topical dapsone with other agents associated with methemoglobinemia may have additive effects and theoretically increase the risk of drug-induced methemoglobinemia.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.g., cyanosis, hypoxia).', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, Adapalene, Clofazimine', 'Vitamin A, Isotretinoin, Dexamethasone, Fluorometholone, Dapsone, Azelaic acid, Adapalene, Dapsone, Clofazimine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239763/', '[1] "Product Information. Aczone (dapsone topical)." QLT USA, Inc  (2005):[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236902, 'Etidocaine', 'Dapsone (topical)', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Meloxicam', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239764/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236903, 'Dapsone (topical)', 'Levobupivacaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Methylprednisolone, Azelaic acid, Adapalene, Clofazimine', 'Meloxicam', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239765/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236904, 'Dapsone (topical)', 'Mepivacaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Meloxicam', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239768/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236905, 'Dapsone (topical)', 'Procaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Meloxicam, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Triamcinolone, Zinc gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239769/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236906, 'Dapsone (topical)', 'Ropivacaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Fluorometholone, Tretinoin, Methylprednisolone, Azelaic acid, Adapalene, Clofazimine', 'Meloxicam', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239771/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236907, 'Dapsone (topical)', 'Silver nitrate (topical)', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239772/', '[1] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT "Acquired methemoglobinemia." West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M "Severe methemoglobinaemia due to benzocaine-containing ''burn cream'': two case reports in an adult and in a child." Burns 37 (2011):  e63-6[4] Gala HC, Madave A "An unusual case of neonatal methemoglobinemia." Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a "Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center''s four-year experience." J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R "Topical antimicrobial agents for pediatric burns." Burns Trauma 5 (2017):  33', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236908, 'Dapsone (topical)', 'Silver sulfadiazine (topical)', 'Moderate', 'Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239773/', '[1] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[2] Geffner ME, Powars DR, Choctaw WT "Acquired methemoglobinemia." West J Med 134 (1981):  7-10[3] Poredos P, Gradisek P, Testen C, Derganc M "Severe methemoglobinaemia due to benzocaine-containing ''burn cream'': two case reports in an adult and in a child." Burns 37 (2011):  e63-6[4] Gala HC, Madave A "An unusual case of neonatal methemoglobinemia." Indian Pediatr 54 (2017):  163[5] Reese AD, Keyloun JW, Garg G, et.a "Compounded cerium nitrate-silver sulfadiazine cream is safe and effective for the treatment of burn wounds: a burn center''s four-year experience." J Burn Care Res 20 (2021):  Epub ahead of print[6] Cartotto R "Topical antimicrobial agents for pediatric burns." Burns Trauma 5 (2017):  33', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236909, 'Dapsone (topical)', 'Tetracaine', 'Major', 'Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.', NULL, 'Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Methylprednisolone, Azelaic acid, More', 'Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Triamcinolone, Zinc gluconate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/239775/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):[3] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009):  837-45[4] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011):  757-61[5] "Product Information. Zynrelef (bupivacaine-meloxicam)." Heron Therapeutics  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236910, 'Berotralstat', 'Nifedipine', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Clevidipine, Celecoxib, Levamlodipine, Acetylsalicylic acid, Bisoprolol, Atenolol, Sotalol', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240576/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236911, 'Bromocriptine', 'Nifedipine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine.  Orally administered bromocriptine is extensively metabolized in the gastrointestinal tract and liver by CYP450 3A4, with approximately 93% of the absorbed dose undergoing first-pass metabolism and only the remaining 7% reaching systemic circulation.  As such, inhibitors of CYP450 3A4 may markedly reduce the metabolic clearance of bromocriptine.', NULL, 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', NULL, 'Caution and close monitoring for development of adverse effects are advisable during coadministration of bromocriptine with CYP450 3A4 inhibitors, and the bromocriptine dosage adjusted as necessary.', 'Metabolism', 'Opicapone, Rotigotine, Tolcapone, Pergolide, Amantadine, Ritodrine, Bremelanotide, Black cohosh', 'Felodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Nimodipine, Felodipine, Acetylsalicylic acid, Ivabradine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240578/', '[1] Nelson MV, Berchou RC, Kareti D, Le Witt PA "Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine." Clin Pharmacol Ther 47 (1990):  694-7[2] "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation  (2001):[3] von Rosenstiel NA, Adam D "Macrolide antibacterials. Drug interactions of clinical significance." Drug Saf 13 (1995):  105-22[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Periti P, Mazzei T, Mini E, Novelli A "Pharmacokinetic drug interactions of macrolides." Clin Pharmacokinet 23 (1992):  106-31[7] "Product Information. Cycloset (bromocriptine)." Valeant Pharmaceuticals  (2018):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236912, 'Dexmethylphenidate', 'Nifedipine', 'Moderate', 'Methylphenidate and other derivative amphetamines may decrease the therapeutic effects of antihypertensive drugs.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.', NULL, 'Caution and monitoring of blood pressure is recommended if methylphenidate, dexmethylphenidate or serdexmethylphenidate are administered with antihypertensives agents such as:  potassium-sparing and thiazide diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers or centrally acting alpha-2 receptor agonists.  The dosage of the antihypertensive drug should be adjusted as needed.', 'Antagonism', 'Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dextroamphetamine, Citicoline', 'Celecoxib, Acetylsalicylic acid, Ivabradine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240582/', '[1] "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):[2] "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc  (2022):[3] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):[4] "Product Information. Metadate ER (methylphenidate)." Celltech Pharmaceuticals Inc  (2002):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical  (2013):[8] "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236913, 'Drospirenone', 'Nifedipine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme.', NULL, 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.', NULL, 'Caution and close clinical monitoring are recommended when drospirenone is prescribed with CYP450 3A4 inhibitors, particularly in patients requiring long-term concomitant use and those with other risk factors for hyperkalemia (e.g., renal insufficiency; coadministration with medications that can increase potassium such as aldosterone antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, and heparin).  Consider checking serum potassium levels during the first treatment cycle and periodically thereafter as indicated.', 'Metabolism', 'Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Medroxyprogesterone acetate, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, More', 'Felodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Nimodipine, Felodipine, Propranolol, Metoprolol, Carvedilol, Nebivolol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240583/', '[1] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation  (2011):[2] "Product Information. Slynd (drospirenone)." Exeltis USA, Inc.  (2022):[3] "Product Information. Angeliq (drospirenone-estradiol)." Bayer Pharmaceutical Inc  (2017):[4] "Product Information. Slinda (drospirenone)." Besins Healthcare Australia Pty Ltd  (2021):[5] "Product Information. Angeliq 1/2 (drospirenone-estradiol)." Bayer Australia Limited  (2021):[6] "Product Information. Slynd (drospirenone)." Duchesnay Inc  (2021):[7] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb  (2022):[8] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb Australia Pty Ltd  (2023):[9] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb Pharmaceuticals Ltd  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236914, 'Hydralazine', 'Nifedipine', 'Moderate', 'Concomitant treatment with other antihypertensive agents or vasodilators, including alpha-adrenoreceptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic blockers, calcium channel blockers, diuretics and nitrates, may potentiate the hypotensive effects of hydralazine and dihydralazine.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', NULL, 'Blood pressure and heart rate should be closely monitored when hydralazine or dihydralazine is used with other agents that can induce hypotension.', 'Synergism', 'Nitroprusside, Diazoxide', 'Nebivolol, Ivabradine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240590/', '[1] "Product Information. Apresoline (hydralazine)." Sterimax Inc  (2022):[2] "Product Information. Hydralazine (hydralazine)." Advanz Pharma  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236915, 'Iobenguane (I-123)', 'Nifedipine', 'Moderate', 'Coadministration with drugs that block norepinephrine uptake or deplete norepinephrine stores may decrease iobenguane I-123 uptake in neuroendocrine tumors and lead to false-negative imaging results.', NULL, 'When medically feasible, any drug that blocks norepinephrine uptake or deplete norepinephrine stores should be discontinued for at least five biological half-lives before iobenguane I-123 administration.', NULL, 'When medically feasible, any drug that blocks norepinephrine uptake or deplete norepinephrine stores should be discontinued for at least five biological half-lives before iobenguane I-123 administration.  Patients should be monitored for the occurrence of clinically significant withdrawal symptoms, especially patients with elevated levels of circulating catecholamines and their metabolites.', 'Distribution', 'Celecoxib, Propranolol, Metoprolol, Carvedilol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240592/', '[1] "Product Information. AdreView (iobenguane I-123)." GE Healthcare  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236916, 'Pralsetinib', 'Nifedipine', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Clevidipine, Levamlodipine, Propranolol, Metoprolol, Nebivolol, Bisoprolol, Acetylsalicylic acid, Atenolol', 'Dacomitinib, Tepotinib, Vemurafenib, Vandetanib, Capmatinib, Afatinib, Tivozanib, Sunitinib, Regorafenib, Alpelisib, Lenvatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240607/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236917, 'Pyrophosphoric acid', 'Nifedipine', 'Moderate', 'Medicinal products including sodium heparin, prazosin, methyldopa, hydralazine, quinidine, beta blockers, calcium channel blockers, digitalis glycosides, nitrates, anthracyclines, and iodinated contrast agents may interfere with the blood pool images taken using Technetium Tc 99m pyrophosphate.  This is characterized by a reduction in the amount of injected radioactivity remaining in the blood pool.', NULL, 'Clinicians should be aware of the possibility of a diagnostic interference.', NULL, 'Clinicians should be aware of the possibility of a diagnostic interference.  When use of iodinated contrast media is anticipated, it is recommended to perform the scintigraphy with (99mTc)-labeled red blood cells prior to administration of the iodinated contrast media to avoid adversely affecting the red blood cell labeling.', 'Distribution', 'Mibefradil, Celecoxib, Acetylsalicylic acid, Ivabradine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240608/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Pyrophosphate (pyrophosphate)." Pharmalucence Inc  (2012):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236918, 'Remimazolam', 'Nifedipine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Celecoxib, Acetylsalicylic acid, Ivabradine', 'Chloral hydrate, Flurazepam, Quazepam, Paraldehyde, Eszopiclone, Ramelteon, Scopolamine, Estazolam, Ethchlorvynol, Tasimelteon, Melatonin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240611/', '[1] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998):  595', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236919, 'Rifampicin', 'Nifedipine', 'Major', 'Potent inducers of CYP450 3A4 such as rifampin may significantly decrease the oral bioavailability of calcium channel blockers, the majority of which are primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of oral calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of oral calcium channel blockers with potent CYP450 3A4 inducers should generally be avoided.  Some authorities consider the combination of nifedipine or nisoldipine with rifampin to be contraindicated.', 'Metabolism', 'Clevidipine, Mibefradil, Nebivolol, Sotalol', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Cycloserine, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240612/', '[1] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992):  711-6[2] Tsuchihashi K, Fukami K, Kishimoto H, et al. "A case of variant angina exacerbated by administration of rifampicin." Heart Vessels 3 (1987):  214-7[3] Tada Y, Tsuda Y, Otsuka T, et al. "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992):  25-7[4] Atmar RL, Greenberg SB, Quarles JM, et al. "Safety and pharmacokinetics of rimantadine small-particle aerosol." Antimicrob Agents Chemother 34 (1990):  2228-33[5] Tada Y, Tsuda Y, Takeshi O, et al. "Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension." Am J Med Sci 303 (1992):  25-7[6] Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H "The nifedipine-rifampin interaction - evidence for induction of gut wall metabolism." Drug Metab Dispos 24 (1996):  1121-3', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236920, 'Fenfluramine', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Dexfenfluramine, Naltrexone, Ephedrine, Phentermine, Orlistat, Diethylpropion, Mazindol, Lacosamide', 'Amisulpride, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240637/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236921, 'Melatonin', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', 'Ethchlorvynol, Zopiclone, Nitrazepam', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240641/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236922, 'Methohexital', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', 'Ethchlorvynol, Zopiclone, Nitrazepam, Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240642/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236923, 'Botulinum toxin type A', 'Loxapine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', 'Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240646/', '[1] "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals[2] "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc[3] "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc[4] "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):[5] "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.  (2022):[6] "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236924, 'Botulinum toxin type B', 'Loxapine', 'Moderate', 'Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.', NULL, 'Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.', 'Synergism', 'Quetiapine, Asenapine, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, Cariprazine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240648/', '[1] "Product Information. Myobloc (rimabotulinumtoxinB)." Elan Pharmaceuticals[2] "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc[3] "Product Information. Botox (onabotulinumtoxinA)." Allergan Inc[4] "Product Information. Xeomin (incobotulinumtoxinA)." Merz Pharmaceuticals  (2022):[5] "Product Information. Jeuveau (prabotulinumtoxinA)." Evolus, Inc.  (2022):[6] "Product Information. Daxxify (daxibotulinumtoxinA)." Revance Therapeutics, Inc.  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236925, 'Safinamide', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240649/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236926, 'Selegiline', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240650/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236927, 'Thiopental', 'Loxapine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Amisulpride, Quetiapine, Pimavanserin, Risperidone', 'Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Ethchlorvynol, Zopiclone, Nitrazepam', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240652/', '[1] Hamilton MJ, Bush M, Smith P, Peck AW "The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man." Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C "Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination." Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. "Propranolol and sotalol metabolism after a drinking party." Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF "Effects of acute alcohol administration on propranolol absorption." Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF "The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam." Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM "Diazepam actions and plasma concentrations following ethanol ingestion." Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A "Profound hypothermia on combined lithium carbonate and diazepam treatment." Br Med J 2 (1977):  22[9] Stovner J, Endresen R "Intravenous anaesthesia with diazepam." Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF "Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation." J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE "Interaction of diazepam with the muscle-relaxant drugs." Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Propranolol interactions with diazepam, lorazepam and alprazolam." Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF "Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic." Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I "Midazolam-morphine sedative interaction in patients." Anesth Analg 68 (1989):  282-5[15] "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G "The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine." Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995):  603-9[19] "Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):[20] "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):[21] "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals  (2001):[23] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company  (2001):[24] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals  (2001):[25] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998):  2200-11[26] "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):[27] "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF "A fatal interaction of methocarbamol and ethanol in an accidental poisoning." J Forensic Sci 35 (1990):  477-82[29] Plushner SL "Valerian: valeriana officinalis." Am J Health Syst Pharm 57 (2000):  328-35[30] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc  (2002):[31] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[33] Cerner Multum, Inc. "Australian Product Information." O 0[34] "Product Information. Fycompa (perampanel)." Eisai Inc  (2012):[35] "Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):[36] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236928, 'Brentuximab vedotin', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240790/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236929, 'Brentuximab vedotin', 'Berotralstat', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.  In vitro, MMAE was found to be a substrate of the P-gp efflux transporter.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.', NULL, 'Caution is advised when brentuximab is used with P-gp inhibitors.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Excretion', 'Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240792/', '[1] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc  (2011):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236930, 'Brentuximab vedotin', 'Selinexor', 'Moderate', 'Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.', NULL, 'The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240864/', '[1] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp"   (2006):[4] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):[5] "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc  (2011):[6] "Product Information. Danyelza (naxitamab)." Y-mAbs Therapeutics  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236931, 'Brentuximab vedotin', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.  Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy.  A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).  Current local immunization guidelines should be consulted for recommendations.  In patients who have recently been vaccinated, such therapy should not be initiated for at least 2 weeks (may be longer in some cases; refer to individual product labeling).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240885/', '[1] "Product Information. Meruvax II (rubella virus vaccine)." Merck & Co., Inc  (2022):[2] "Product Information. Attenuvax (measles virus vaccine)." Merck & Co., Inc  (2022):[3] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur  (2001):[4] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):[5] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[6] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Co., Inc  (2002):[7] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011):  1495-7[8] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014):  161[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] "Product Information. DENGVAXIA (dengue vaccine)." sanofi pasteur  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236932, 'Brentuximab vedotin', 'Varicella Zoster Vaccine (Recombinant)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.', NULL, 'In general, the U.', NULL, 'In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual''s risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240886/', '[1] "Product Information. Fluzone (influenza virus vaccine, inactivated)." Connaught Laboratories Inc[2] "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham[3] "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] "Product Information. Imovax Rabies (rabies vaccine, human diploid cell)." sanofi pasteur  (2022):[6] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf"   (2019):[10] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf"   (2019):[11] CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html"   (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236933, 'Aldesleukin', 'Tadalafil', 'Minor', 'Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications.  These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.', NULL, 'Patients should be advised of the potential for interaction and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.', NULL, 'Patients should be advised of the potential for interaction and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.', 'Synergism', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, More', 'Darifenacin, Vardenafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240887/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):[2] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals  (2008):[3] "Product Information. Entadfi (finasteride-tadalafil)." Veru Inc  (2021):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236934, 'Tadalafil', 'Avanafil', 'Major', 'The safety and efficacy of combining a phosphodiesterase-5 (PDE5) inhibitor with other PDE-5 inhibitors or other treatments for erectile dysfunction have not been studied.  Since these agents have systemic vasodilatory properties, concurrent use may result in additive hypotensive and other cardiovascular adverse effects.', NULL, 'Concomitant use of a PDE5 inhibitor with another PDE5 inhibitor should generally be avoided.', NULL, 'Concomitant use of a PDE5 inhibitor with another PDE5 inhibitor should generally be avoided.', 'Synergism', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Phenyl salicylate, More', 'Darifenacin, Ammonium chloride, Apomorphine, Yohimbine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Avanafil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240892/', '[1] "Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):[2] "Product Information. Levitra (vardenafil)." Bayer  (2003):[3] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):[4] "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):[8] "Product Information. Stendra (avanafil)." Vivus Inc  (2012):[9] "Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236935, 'Entrectinib', 'Tadalafil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.  Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects.  Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone.  Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Oxybutynin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240898/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236936, 'Eslicarbazepine', 'Tadalafil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', NULL, 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.', NULL, 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.  However, the possibility of diminished pharmacologic effects of tadalafil should be considered.  For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.', 'Metabolism', 'Brivaracetam, Ezogabine, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More', 'Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Papaverine, Vardenafil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240899/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236937, 'Tadalafil', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if tadalafil is prescribed with CYP450 3A4 inhibitors.  Dosage adjustments may be appropriate for tadalafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects.  Tadalafil labeling recommends that the dosage not exceed 10 mg once every 72 hours in patients treated concomitantly with a potent CYP450 3A4 inhibitor, such as erythromycin, itraconazole, ketoconazole, protease inhibitors, and nefazodone.  Patients should be advised to promptly notify their physician if they experience potential symptoms of PDE5 inhibitor toxicity such as pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours).', 'Metabolism', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240913/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236938, 'Tadalafil', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, Afatinib, More', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240916/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation  (2020):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236939, 'Amikacin', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, Benzylpenicillin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240952/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236940, 'Amikacin (liposome)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, Benzylpenicillin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240953/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236941, 'Amphotericin B', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240954/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236942, 'Amphotericin B (cholesteryl sulfate)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240955/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236943, 'Amphotericin B (liposomal)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240956/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236944, 'Adefovir dipivoxil', 'Bacitracin', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240957/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236945, 'Adefovir dipivoxil', 'Balsalazide', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Budesonide, Hydrocortisone, Cromoglicic acid, Prednisone, Betamethasone, Beclomethasone dipropionate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240958/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236946, 'Human botulinum neurotoxin A/B immune globulin', 'Adefovir dipivoxil', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients.  Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy.  Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.  If renal function deteriorates, discontinuation of the product should be considered.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240960/', '[1] "Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring LLC  (2002):[2] "Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc  (2005):[3] "Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises  (2008):[4] "Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation  (2013):[5] MMWR Morb Mortal Wkly Rep "Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm"   (2013):[6] Pusey EY, Levy JB "Nephrotoxicity of intravenous immunoglobulin.  http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html"   (2013):[7] KDIGO. Kidney Disease Improving Global Outcomes "KDIGO clinical practice guideline for acute kidney injury.  http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf"   (2013):[8] Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[9] Perazella MA "Renal vulnerability to drug toxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[10] Naughton CA "Drug-induced nephrotoxicity.  http://www.aafp.org/afp/2008/0915/p743.html"   (2013):[11] Moses S "Nephrotoxic drugs, drug-induced nephrotoxicity.  http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm"   (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236947, 'Adefovir dipivoxil', 'Bromfenac', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240961/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236948, 'Adefovir dipivoxil', 'Cabozantinib', 'Moderate', 'Coadministration of cabozantinib with multidrug resistance-associated proteins (MRP2) inhibitors may increase exposure and toxicity of cabozantinib.', NULL, 'Caution is advised if cabozantinib is used concomitantly with a MRP2 inhibitor.', NULL, 'Caution is advised if cabozantinib is used concomitantly with a MRP2 inhibitor.  Monitor for cabozantinib toxicity, such as gastrointestinal perforations and fistulas, hemorrhage, thrombotic events, hypertension, diarrhea, and palmar-plantar erythrodysesthesia.  Dose reductions, interruption or discontinuation of cabozantinib may be necessary if toxicity occurs.', 'Distribution', 'Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240962/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):[4] "Product Information. Cabometyx (cabozantinib)." Exelixis Inc  (2016):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236949, 'Adefovir dipivoxil', 'Capreomycin', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240963/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236950, 'Celecoxib', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240964/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236951, 'Cidofovir', 'Adefovir dipivoxil', 'Major', 'Coadministration of cidofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney.  Dose-related nephrotoxicity is the major toxicity of cidofovir.', NULL, 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.', NULL, 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) is considered contraindicated.  Such agents should be discontinued for at least seven days prior to starting therapy with cidofovir.  Initiation of cidofovir is also contraindicated in patients with a serum creatinine >1.5 mg/dL, a calculated creatinine clearance <=55 mL/min, or a urine protein >=100 mg/dL (2+ proteinuria or greater).', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240965/', '[1] "Product Information. Vistide (cidofovir)." Gilead Sciences  (2001):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236952, 'Cimetidine', 'Adefovir dipivoxil', 'Moderate', 'Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Excretion', 'Paritaprevir, Glecaprevir, Cabotegravir, Simeprevir, Zanamivir, Lenacapavir, Telaprevir, Oseltamivir, Cobicistat, Brincidofovir, Stavudine, More', 'Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Nizatidine, Esomeprazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240966/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236953, 'Cisplatin', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240967/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236954, 'Cladribine', 'Adefovir dipivoxil', 'Moderate', 'The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', NULL, 'Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.', 'Antagonism', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240968/', '[1] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid"   (2007):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236955, 'Clofarabine', 'Adefovir dipivoxil', 'Moderate', 'Coadministration of clofarabine with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney.  Moreover, renal impairment secondary to the use of these agents may reduce the clearance of clofarabine, which is primarily eliminated by renal excretion.', NULL, 'Drugs that are potentially nephrotoxic (e.', NULL, 'Drugs that are potentially nephrotoxic (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, carboplatin, cisplatin, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) should be avoided during the 5 days of clofarabine administration if possible.  Renal function should be evaluated prior to and during therapy, and administration discontinued immediately if substantial increases (e.g., grade 3 or higher) in creatinine are noted.  Clofarabine therapy should be reinstated when the patient is stable and renal function has returned to baseline, generally with a 25% dose reduction.', 'Synergism, Excretion', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, Oseltamivir, More', 'Fluorouracil, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240969/', '[1] "Product Information. Clolar (clofarabine)." sanofi-aventis  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236956, 'Cobicistat', 'Adefovir dipivoxil', 'Moderate', 'Cobicistat may increase the plasma concentrations of antiretroviral agents.  The plasma concentrations of cobicistat may also be increased or reduced in the presence of antiretroviral agents.  The proposed mechanism is cobicistat inhibition of the CYP450 3A4 isoenzyme, of which antiretroviral agents may be substrates, and the inhibition or induction of CYP450 3A4 by concomitant antiretroviral medications.  Cobicistat is a mechanism-based inhibitor and substrate of CYP450 3A4 with no antiretroviral activity of its own.  Rather, it is indicated in its capacity as a pharmacokinetic booster of CYP450 3A4 to increase the systemic exposure of some antiretroviral medications such as atazanavir, darunavir, and elvitegravir, which are substrates of this isoenzyme.  Concomitant use of other antiretroviral agents with cobicistat may also increase the plasma levels and risk of side effects associated with these medicines.  In contrast, concomitant use of cobicistat-boosted atazanavir or darunavir with CYP450 3A4 inducers nevirapine, etravirine, or efavirenz may reduce the plasma concentrations of cobicistat, darunavir, and atazanavir, leading to a potential loss of therapeutic effect and development of resistance to darunavir and atazanavir.  Pharmacokinetic data are not available.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor.  In addition, cobicistat should not be used concomitantly with ritonavir due to their similar effects on CYP450 3A4.  According to some authorities, use of the antiretroviral combinations of atazanavir-cobicistat or darunavir-cobicistat concomitantly with the CYP450 3A4 inducers efavirenz, etravirine, or nevirapine is also not recommended.  Other authorities consider the administration of atazanavir-cobicistat with efavirenz or nevirapine to be contraindicated.  Since dosing recommendations have only been established for a number of antiretroviral medications, product labeling and current antiretroviral treatment guidelines should be consulted.', 'Metabolism', 'Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Remdesivir, Famciclovir, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240970/', '[1] "Product Information. Viramune (nevirapine)." Boehringer-Ingelheim  (2001):[2] "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals  (2001):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Prezista (darunavir)." Ortho Biotech Inc  (2006):[5] "Product Information. Intelence (etravirine)." Ortho Biotech Inc  (2008):[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences  (2012):[8] "Product Information. Tybost (cobicistat)." Gilead Sciences  (2014):[9] "Product Information. Prezcobix (cobicistat-darunavir)." Janssen Pharmaceuticals  (2014):[10] "Product Information. Evotaz (atazanavir-cobicistat)." Bristol-Myers Squibb  (2015):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236957, 'Colistimethate', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240971/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236958, 'Human cytomegalovirus immune globulin', 'Adefovir dipivoxil', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients.  Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy.  Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.  If renal function deteriorates, discontinuation of the product should be considered.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Bezlotoxumab, Palivizumab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240972/', '[1] "Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring LLC  (2002):[2] "Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc  (2005):[3] "Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises  (2008):[4] "Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation  (2013):[5] MMWR Morb Mortal Wkly Rep "Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm"   (2013):[6] Pusey EY, Levy JB "Nephrotoxicity of intravenous immunoglobulin.  http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html"   (2013):[7] KDIGO. Kidney Disease Improving Global Outcomes "KDIGO clinical practice guideline for acute kidney injury.  http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf"   (2013):[8] Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[9] Perazella MA "Renal vulnerability to drug toxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[10] Naughton CA "Drug-induced nephrotoxicity.  http://www.aafp.org/afp/2008/0915/p743.html"   (2013):[11] Moses S "Nephrotoxic drugs, drug-induced nephrotoxicity.  http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm"   (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236959, 'Deferasirox', 'Adefovir dipivoxil', 'Major', 'Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents.', NULL, 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections.  Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations.  A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy.  Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.  In clinical studies, the daily dosage of deferasirox was reduced by 10 mg/kg for increases of serum creatinine on two consecutive measures (i.e., >33% in patients older than 15 years of age, or >33% and greater than the age-appropriate upper limit of normal in patients younger than 15 years of age).  Care should be taken to maintain adequate hydration in patients who develop diarrhea or vomiting.', 'Synergism', 'Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240973/', '[1] "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):[2] Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M "Fanconi Syndrome Due to Deferasirox." Am J Kidney Dis  (2009):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236960, 'Diatrizoate', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240974/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236961, 'Diclofenac', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, Cobicistat, More', 'Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Fluocinolone acetonide, Cortisone, Hydrocortisone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240975/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236962, 'Diflunisal', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240976/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236963, 'Entecavir', 'Adefovir dipivoxil', 'Moderate', 'Because entecavir is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of entecavir and/or the coadministered drug.', NULL, 'Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.', NULL, 'Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with entecavir.  Dosage adjustment is required in patients with renal insufficiency (creatinine clearance below 50 mL/min) at baseline or during treatment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240978/', '[1] "Product Information. Baraclude (entecavir)." Bristol-Myers Squibb  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236964, 'Etidronic acid', 'Adefovir dipivoxil', 'Moderate', 'Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents).  Renal function and serum electrolytes should be monitored.  Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.  In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240979/', '[1] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG "Effects of intravenous diphosphonates on renal function." Lancet 1 (1983):  1328[2] "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals  (2001):[3] Osullivan TL, Akbari A, Cadnapaphornchai P "Acute renal failure associated with the administration of parenteral etidronate." Ren Fail 16 (1994):  767-73[4] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M "Acute renal failure and alendronate." Nephrol Dial Transplant 12 (1997):  2797-8[5] "Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):[6] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D "Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases." Nephron 89 (2001):  467-8[7] Lockridge L, Papac RJ, Perazella MA "Pamidronate-associated nephrotoxicity in a patient with Langerhans''s histiocytosis." Am J Kidney Dis 40 (2002):  E2[8] Markowitz GS, Fine PL, Stack JI, et al. "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)." Kidney Int 64 (2003):  281-289[9] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003):  E18[10] Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003):  1676-9; discussion 1676-9[11] "Product Information. Ostac (clodronate)." Hoffmann-La Roche Limited  (2004):[12] "Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236965, 'Etodolac', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240980/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236966, 'Exenatide', 'Adefovir dipivoxil', 'Moderate', 'Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide.', NULL, 'Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.', NULL, 'Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.', 'Synergism', 'Lamivudine, Cabotegravir, Maraviroc, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Dolutegravir, Oseltamivir, More', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Tolbutamide, Miglitol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240981/', '[1] "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236967, 'Fenoprofen', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240982/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236968, 'Flecainide', 'Adefovir dipivoxil', 'Moderate', 'Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Dolutegravir, More', 'Amiodarone, Dronedarone, Tocainide, Propafenone, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240983/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236969, 'Flucytosine', 'Adefovir dipivoxil', 'Moderate', 'Drugs that impair glomerular filtration may prolong the half-life of flucytosine and lead to accumulation.  Prolonged flucytosine serum concentrations of greater than 100 mcg/mL may increase the risk of gastrointestinal, hepatic, and hematologic toxicity.', NULL, 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.', NULL, 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function and flucytosine blood levels should be closely monitored during therapy, and the dose or dosing interval should be adjusted to maintain flucytosine concentrations below 100 mcg/mL.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Micafungin, Caspofungin, Itraconazole, Posaconazole, Oteseconazole, Ketoconazole, Anidulafungin, Voriconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240984/', '[1] "Product Information. Ancobon (flucytosine)." Roche Laboratories  (2002):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236970, 'Flurbiprofen', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Chlorhexidine, Povidone-iodine, Salicylic acid, Fluocinolone acetonide, Cortisone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240985/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236971, 'Foscarnet', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240986/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236972, 'Gallium nitrate', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240987/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236973, 'Ganciclovir', 'Adefovir dipivoxil', 'Moderate', 'Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240988/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236974, 'Gentamicin', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Ciprofloxacin, Famciclovir, Cefuroxime, Trifluridine, Moxifloxacin, Benzylpenicillin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240989/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236975, 'Givosiran', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240990/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236976, 'Ibandronate', 'Adefovir dipivoxil', 'Moderate', 'Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents).  Renal function and serum electrolytes should be monitored.  Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.  In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240991/', '[1] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG "Effects of intravenous diphosphonates on renal function." Lancet 1 (1983):  1328[2] "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals  (2001):[3] Osullivan TL, Akbari A, Cadnapaphornchai P "Acute renal failure associated with the administration of parenteral etidronate." Ren Fail 16 (1994):  767-73[4] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M "Acute renal failure and alendronate." Nephrol Dial Transplant 12 (1997):  2797-8[5] "Product Information. Zometa (zoledronic acid)." Novartis Pharmaceuticals  (2001):[6] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D "Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases." Nephron 89 (2001):  467-8[7] Lockridge L, Papac RJ, Perazella MA "Pamidronate-associated nephrotoxicity in a patient with Langerhans''s histiocytosis." Am J Kidney Dis 40 (2002):  E2[8] Markowitz GS, Fine PL, Stack JI, et al. "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)." Kidney Int 64 (2003):  281-289[9] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003):  E18[10] Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003):  1676-9; discussion 1676-9[11] "Product Information. Ostac (clodronate)." Hoffmann-La Roche Limited  (2004):[12] "Product Information. Boniva (ibandronate)." Roche Laboratories  (2005):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236977, 'Human immunoglobulin G (intravenous)', 'Adefovir dipivoxil', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients.  Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy.  Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.  If renal function deteriorates, discontinuation of the product should be considered.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240992/', '[1] "Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring LLC  (2002):[2] "Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc  (2005):[3] "Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises  (2008):[4] "Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation  (2013):[5] MMWR Morb Mortal Wkly Rep "Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm"   (2013):[6] Pusey EY, Levy JB "Nephrotoxicity of intravenous immunoglobulin.  http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html"   (2013):[7] KDIGO. Kidney Disease Improving Global Outcomes "KDIGO clinical practice guideline for acute kidney injury.  http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf"   (2013):[8] Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[9] Perazella MA "Renal vulnerability to drug toxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[10] Naughton CA "Drug-induced nephrotoxicity.  http://www.aafp.org/afp/2008/0915/p743.html"   (2013):[11] Moses S "Nephrotoxic drugs, drug-induced nephrotoxicity.  http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm"   (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236978, 'Human immunoglobulin G (intravenous and subcutaneous)', 'Adefovir dipivoxil', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  The manufacturers recommend administering immune globulin infusions at the minimum concentration available and at the minimum rate of infusion feasible in such patients.  Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy.  Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.  If renal function deteriorates, discontinuation of the product should be considered.  Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240993/', '[1] "Product Information. Cytogam (cytomegalovirus immune globulin)." CSL Behring LLC  (2002):[2] "Product Information. Respigam (respiratory syncytial virus immune globulin)." Medimmune Inc  (2005):[3] "Product Information. BabyBIG (botulism immune globulin)." FFF Enterprises  (2008):[4] "Product Information. Bivigam (immune globulin intravenous)." Biotest Pharmaceuticals Corporation  (2013):[5] MMWR Morb Mortal Wkly Rep "Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm"   (2013):[6] Pusey EY, Levy JB "Nephrotoxicity of intravenous immunoglobulin.  http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html"   (2013):[7] KDIGO. Kidney Disease Improving Global Outcomes "KDIGO clinical practice guideline for acute kidney injury.  http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf"   (2013):[8] Guo X, Nzerue C "How to prevent, recognize, and treat drug-induced nephrotoxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[9] Perazella MA "Renal vulnerability to drug toxicity.  http://www.ccjm.org/content/69/4/289.full.pdf"   (2013):[10] Naughton CA "Drug-induced nephrotoxicity.  http://www.aafp.org/afp/2008/0915/p743.html"   (2013):[11] Moses S "Nephrotoxic drugs, drug-induced nephrotoxicity.  http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm"   (2013):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236979, 'Inotersen', 'Adefovir dipivoxil', 'Major', 'Coadministration of inotersen with other nephrotoxic agents may increase the risk of renal impairment due to additive adverse effects on the kidney.', NULL, 'Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.', NULL, 'Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) .  Serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and a urinalysis should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling.  Inotersen should generally not be initiated in patients with a UPCR of 1000 mg/g or higher, or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines.  Patients or their caregivers should be apprised of the signs and symptoms of glomerulonephritis and to seek medical attention if they occur, including edema, shortness of breath, coughing, hematuria, and decreased urination.  Inotersen should be withheld in patients who develop a UPCR of 1000 mg/g or higher, or eGFR below 45 mL/minute/1.73 m2, pending further evaluation of the cause.  Weekly dosing may be resumed once eGFR increases to at least 45 mL/minute/1.73 m2, UPCR decreases to below 1000 mg/g, or the underlying cause of the renal function decline is corrected.  In patients with UPCR of 2000 mg/g or higher, perform further evaluation for acute glomerulonephritis as clinically indicated.  If acute glomerulonephritis is confirmed, inotersen should be permanently discontinued.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240994/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Tegsedi (inotersen)." Akcea Therapeutics  (2018):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236980, 'Iobenguane (I-131)', 'Adefovir dipivoxil', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240995/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236981, 'Iodipamide', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240997/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236982, 'Iodixanol', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240998/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236983, 'Iohexol', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/240999/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236984, 'Iopamidol', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241001/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236985, 'Iopromide', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241002/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236986, 'Iothalamic acid', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241003/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236987, 'Ioversol', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241004/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236988, 'Ioxilan', 'Adefovir dipivoxil', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment.Pathogenesis has not been fully elucidated, but may involve renal hypoperfusion and ischemia, direct cytotoxicity on tubular epithelial cells, and generation of reactive oxygen species.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.  Otherwise, experts recommend discontinuing other nephrotoxic drugs 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose (100 mL or less) of a nonionic, low-osmolar (e.g., iohexol, iomeprol, iopamidol, iopental, iopromide, ioversol) or iso-osmolar (e.g., iodixanol, iotrolan) contrast medium should be used whenever possible, since the risk of nephrotoxicity may be increased with increasing contrast dose, osmolarity, and ionicity.  Some studies suggest a lower risk for iso-osmolar contrasts compared to low-osmolar contrasts, although data are limited.  Serum creatinine levels should be measured before contrast administration (if procedure is not urgent) and continued for 24 to 48 hours after.  In addition, patients should be adequately hydrated with either intravenous normal saline or sodium bicarbonate starting 3 (outpatient) to 6 (inpatient) hours before and continued for 6 to 24 hours after procedure.  Oral fluids are also beneficial, but not as effective as intravenous hydration.  N-acetylcysteine the day before and day of contrast administration, or theophylline up to 30 minutes before contrast administration, have also been used in high-risk or critically ill patients.  Preferably, a nephrologist should be consulted to optimize prophylactic measures for preventing contrast-induced nephropathy in high-risk patients and to guide treatment if the condition occurs.  Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241006/', '[1] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990):  145-56[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010):  S169-74[3] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012):  723-6[4] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015):  1903-7[5] Bansal R, Aflieco F, Kaplan AA "Contrast-Induced Nephropathy.  http://emedicine.medscape.com/article/246751-overview"   (2016):[6] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005):  361-70[7] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008):  2001', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236989, 'Adefovir dipivoxil', 'Lithium carbonate', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241007/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236990, 'Adefovir dipivoxil', 'Lutetium Lu 177 dotatate', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241008/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236991, 'Adefovir dipivoxil', 'Meclofenamic acid', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241010/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236992, 'Adefovir dipivoxil', 'Mefenamic acid', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241011/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236993, 'Adefovir dipivoxil', 'Meloxicam', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Misoprostol, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241012/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236994, 'Adefovir dipivoxil', 'Memantine', 'Minor', 'Theoretically, the concomitant administration of memantine and other drugs that undergo active renal tubular secretion may result in altered plasma levels of both drugs.', NULL, 'There are fewer studies of drug-drug interactions between memantine and other drugs affecting renal tubular secretion, and the clinical significance is unclear; therefore, no targeted adjustments to the treatment regimen are necessary.', NULL, 'There are fewer studies of drug-drug interactions between memantine and other drugs affecting renal tubular secretion, and the clinical significance is unclear; therefore, no targeted adjustments to the treatment regimen are necessary.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Rivastigmine, Galantamine, Donepezil, Tacrine, Ginkgo biloba, Aducanumab', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241013/', '[1] "Product Information. Namenda (memantine)." Forest Pharmaceuticals  (2003):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236995, 'Adefovir dipivoxil', 'Mesalazine', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Budesonide, Hydrocortisone, Cromoglicic acid, Prednisone, Betamethasone, Beclomethasone dipropionate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241014/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236996, 'Adefovir dipivoxil', 'Methotrexate', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, Dolutegravir, Cobicistat, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241015/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236997, 'Adefovir dipivoxil', 'Methoxyflurane', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Salicylic acid, Acetaminophen, Choline salicylate, Ziconotide, Acetylsalicylic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241016/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236998, 'Adefovir dipivoxil', 'Midodrine', 'Moderate', 'Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma concentrations of adefovir and/or the coadministered drug(s).  The mechanism is competitive inhibition of renal excretion.  Drugs that are thought to undergo active tubular secretion include metformin, cimetidine, ranitidine, procainamide, flecainide, quinidine, triamterene, midodrine, cidofovir, acyclovir, valacyclovir, tenofovir, ganciclovir, and valganciclovir.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', NULL, 'Patients receiving adefovir dipivoxil in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241018/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (236999, 'Adefovir dipivoxil', 'Moxetumomab Pasudotox', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241019/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (237000, 'Adefovir dipivoxil', 'Nabumetone', 'Major', 'Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer''s product labeling.', 'Excretion', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/241020/', '[1] "Product Information. Hepsera (adefovir)." Gilead Sciences  (2022):', 1767369485);
